Portage Biotech Inc is engaged in researching and developing pharmaceutical and biotech products through to clinical proof of concept with an initial focus on unmet clinical needs. Its pipeline products include IMM-60; IMM-65; INT230-6; INTXX and others.

Portage Biotech

Communications Systems, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JCS#NASDAQ">JCS</a>)&nbsp;(&quot;CSI&quot; or the &quot;Company&quot;), formerly an IoT intelligent edge products and services company, today announced that at its Special Shareholder Meeting held today, July 28, 2021, CSI shareholders approved the sale of the Company&#39;s Transition Networks and Net2Edge businesses, which comprise the Company&#39;s Electronics &amp; Software Segment assets, to Lantronix, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LTRX#NASDAQ">LTRX</a>) (&quot;Lantronix&quot;). This Special Shareholder Meeting was called by a notice and proxy statement first mailed or made available on June 15, 2021 to all shareholders of record as of June 11, 2021.
On April 29, 2021, CSI entered into a definitive securities purchase agreement with Lantronix to sell these businesses for a base price of&nbsp;$25.0 million&nbsp;to be paid at closing, subject to a working capital adjustment following the closing, plus up to an additional&nbsp;$7.0 million&nbsp;in earnout payments based on revenue milestones for the Transition Networks and Net2Edge businesses in the two 180-day periods after closing of the sale. As previously announced, the sale of these businesses required CSI shareholder approval and is also subject to customary closing conditions.
With CSI shareholder approval of the sale, CSI expects the transaction with Lantronix to close on or about August 2, 2021. The Company also previously announced that CSI expects to declare a cash dividend of&nbsp;$3.50&nbsp;per share to current shareholders or approximately&nbsp;$35.0 million&nbsp;from the net proceeds from the sale transaction and other available cash resources. The CSI board has not determined the exact timing of the cash dividend or set a record date for CSI shareholders entitled to the dividend. However, the CSI Board expects to make a final decision on the amount and timing of the dividend in due course following the closing of the transaction with Lantronix and CSI will issue a press release with this information at the appropriate time. Additionally, any net proceeds CSI receives from Lantronix from the earnout in connection with the sale transaction will be delivered to CSI shareholders through the contingent value rights (CVRs) to be issued in connection with the previously announced merger transaction with Pineapple Energy LLC (&quot;Pineapple&quot;), a growing U.S. operator and consolidator of residential solar, battery storage, and grid services solutions.
For more information about the previously announced CSI-Pineapple merger visit&nbsp;<a href="https://www.commsystems.com/investor-resources">https://www.commsystems.com/investor-resources</a>
Additional Legacy CSI Assets
Consistent with the announcement of the Pineapple merger transaction, CSI has been devoting its efforts to monetizing CSI&#39;s assets for the benefit of our shareholders by actively pursuing the divestiture of substantially all our current operating and non-operating assets. Following the closing of the sale of the Electronics &amp; Software Segment, CSI&#39;s remaining legacy assets to be sold include the Services &amp; Support Segment (JDL Technologies and Ecessa Corporation), which had revenues of&nbsp;$8.8 million&nbsp;in 2020, the Company&#39;s headquarters building in Minnetonka, Minnesota, currently listed for&nbsp;$10.0 million, and real estate in Hector, Minnesota, currently listed for&nbsp;$975,000. As previously disclosed, in addition to any cash dividends paid prior to the CSI-Pineapple merger, CSI shareholders immediately prior to this merger (i) will receive a CVR that will entitle them to participate in distributions of the net proceeds from earnouts related to the Lantronix transaction and the sale of the remaining CSI legacy assets and (ii) will continue to own the same number of shares of CSI common stock immediately following the closing and therefore have an interest as shareholders in the post-merger CSI that will commence doing business as Pineapple Energy, with a business model focused on the rapidly growing home solar industry.
About Communications Systems, Inc.
Communications Systems, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JCS#NASDAQ">JCS</a>), which has operated as an IoT intelligent edge products and services company, has announced its planned merger with Pineapple Energy. After the Pineapple merger, the Company will be positioned to grow organically and to acquire and grow leading local and regional solar, storage, and energy services companies nationwide. The vision is to power the energy transition through grass-roots growth of solar electricity paired with battery storage on consumers&#39; homes.
Website Information
CSI routinely posts important information for investors on its website,&nbsp;<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.commsystems.com&amp;esheet=52467841&amp;newsitemid=20210728006009&amp;lan=en-US&amp;anchor=www.commsystems.com&amp;index=2&amp;md5=701efb0a894fa33cb76367ccc3a8b8ec">www.commsystems.com</a>, in the &quot;Investor Resources&quot; section. CSI uses this website as a means of disclosing material information in compliance with its disclosure obligations under SEC Regulation FD. Accordingly, investors should monitor the &quot;Investor Resources&quot; section of CSI&#39;s website, in addition to following its press releases, SEC filings, future public conference calls, presentations and webcasts. The information contained on, or that may be accessed through, CSI&#39;s website is not incorporated by reference into, and is not a part of, this document.
Forward Looking Statements
This press release includes certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding future financial performance, future growth and future acquisitions. These statements are based on Communications Systems&#39; current expectations or beliefs and are subject to uncertainty and changes in circumstances. There can be no guarantee that the proposed transactions described in this document will be completed, or that they will be completed as currently proposed, or at any particular time. Actual results may vary materially from those expressed or implied by the statements here due to changes in economic, business, competitive or regulatory factors, and other risks and uncertainties affecting the operation of Communications Systems&#39; business. These risks, uncertainties and contingencies are presented in the Company&#39;s Annual Report on Form 10-K and, from time to time, in the Company&#39;s other filings with the Securities and Exchange Commission. The information set forth herein should be read considering such risks. Further, investors should keep in mind that the Company&#39;s financial results in any period may not be indicative of future results. Communications Systems is under no obligation to, and expressly disclaims any obligation to, update or alter its forward-looking statements, whether because of new information, future events, changes in assumptions or otherwise. In addition to these factors, there are a number of specific factors related to this transaction, including:
<ul>
<li>conditions to the closing of the sale to Lantronix may not be satisfied or the sale may involve unexpected costs, liabilities or delays;</li>
<li>up to&nbsp;$7.0 million&nbsp;of the purchase price is structured in the form of an earnout based on revenues generated by Lantronix in the 360 days following closing, and there is no guaranty that sufficient revenues will be recognized for the earnout to be paid to the Company;</li>
<li>conditions to the closing of the previously announced CSI-Pineapple merger may not be satisfied or the merger may involve unexpected costs, liabilities or delays;</li>
<li>related to the CSI-Pineapple announced merger, the Company&#39;s ability to successfully sell its other legacy operating business assets and its real estate assets at a value close to their current fair market value and distribute these proceeds to its existing shareholder base;</li>
<li>the fact that the continuing CSI-Pineapple entity will be entitled to retain ten percent of the net proceeds of CSI legacy assets that are sold after the effective date of the CSI-Pineapple closing;</li>
<li>the occurrence of any other risks to consummation of the CSI-Pineapple merger, including the risk that the CSI-Pineapple merger will not be consummated within the expected time period or any event, change or other circumstances that could give rise to the termination of the CSI-Pineapple merger;</li>
<li>risks that the Lantronix transaction and the CSI-Pineapple merger will disrupt current CSI plans and operations or that the business or stock price of CSI may suffer as a result of uncertainty surrounding the Lantronix transaction and the CSI-Pineapple merger;</li>
<li>the outcome of any legal proceedings related to the sale to Lantronix or the CSI-Pineapple merger; and</li>
<li>the fact that CSI cannot yet determine the exact amount and timing of any pre-CSI-Pineapple merger cash dividends or the value of the Contingent Value Rights that CSI intends to distribute to its shareholders immediately prior to the effective date of the CSI-Pineapple merger.</li>
</ul>
&nbsp;
<img alt="" src="https://cts.businesswire.com/ct/CT?id=bwnews&amp;sty=20210728006009r1&amp;sid=benz2&amp;distro=nx&amp;lang=en" />
View source version on businesswire.com:&nbsp;<a href="https://www.businesswire.com/news/home/20210728006009/en/">https://www.businesswire.com/news/home/20210728006009/en/</a>

News

Contracts

LTRX

Communication Systems Inc. Announced That Shareholders Approved The Sale Of The Co.'s Transaction Networks And Net2Edge Business Today, July 28.

Guidance

GSHD

Goosehead Insurance Sees FY21 Sales $146M-$156M Vs. $154.79M Est.

Meritage Homes (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MTH#NYSE">MTH</a>) reported quarterly earnings of $4.36 per share which beat the analyst consensus estimate of $3.43 by 27.11 percent. This is a 83.19 percent increase over earnings of $2.38 per share from the same period last year. The company reported quarterly sales of $1.26 billion which beat the analyst consensus estimate of $1.17 billion by 8.03 percent. This is a 22.36 percent increase over sales of $1.03 billion the same period last year.

Earnings

Meritage Homes Q2 EPS $4.36 Beats $3.43 Estimate, Sales $1.26B Beat $1.17B Estimate

Echo Global Logistics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ECHO#NASDAQ">ECHO</a>) reported quarterly earnings of $0.84 per share which beat the analyst consensus estimate of $0.59 by 42.37 percent. This is a 342.11 percent increase over earnings of $0.19 per share from the same period last year. The company reported quarterly sales of $934.52 million which beat the analyst consensus estimate of $861.76 million by 8.44 percent. This is a 81.56 percent increase over sales of $514.72 million the same period last year.

ECHO

Echo Global Logistics Q2 EPS $0.84 Beats $0.59 Estimate, Sales $934.52M Beat $861.76M Estimate

WIIM

Facebook shares are trading lower after the company reported Q2 earnings results and DAUs.

Fusion Pharmaceuticals Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FUSN#NASDAQ">FUSN</a>), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Company&#39;s Investigational New Drug (IND) applications for [225Ac]-FPI-1966 (FPI-1966) and imaging agent [111In]-FPI-1967 (FPI-1967). FPI-1966 is a targeted alpha therapy (TAT) designed to use vofatamab, a human monoclonal antibody, to target and deliver actinium-225 to tumor sites expressing fibroblast growth factor 3 (FGFR3), a protein that is overexpressed in multiple tumor types, particularly head and neck and bladder cancers. FPI-1966 utilizes Fusion&#39;s Fast-Clear&trade; linker to connect vofatamab to actinium-225.
<a href="https://mma.prnewswire.com/media/1196797/Fusion_Pharmaceuticals_Logo.html" target="_blank"><img alt="(PRNewsfoto/Fusion Pharmaceuticals Inc.)" src="https://mma.prnewswire.com/media/1196797/Fusion_Pharmaceuticals_Logo.jpg" /> </a>
&quot;Leveraging Fusion&#39;s platform and expertise developing targeted alpha therapies, we are excited to begin our second clinical program,&quot; said Chief Executive Officer John Valliant, Ph.D. &quot;FGFR3 is an established and validated cancer target which is found in multiple tumor types with substantial unmet need, notably head and neck and bladder cancers. We have an opportunity to selectively deliver alpha particles to these tumors and use precision radiation therapy as a new treatment paradigm. While the currently approved pan-FGFR inhibitor for bladder cancer requires the presence of a specific mutation, our approach requires only over-expression of FGFR3. If successful, this could provide an opportunity to treat a larger population of patients.&quot;
Fusion plans to initiate a Phase 1, non-randomized, open-label clinical trial in patients with solid tumors expressing FGFR3 intended to investigate safety, tolerability and pharmacokinetics and to establish the recommended Phase 2 dose. The study employs a 3 + 3 dose escalation design to evaluate multiple ascending doses of FPI-1966. The first cohort will comprise four sub-groups in which various doses of non-radiolabeled vofatamab (&quot;cold antibody&quot;) will be evaluated to assess the impact of pre-dosing on tumor uptake. As part of the screening process, patients will be administered an imaging analogue of FPI-1966, FPI-1967, and only those who meet predefined tumor uptake and safety criteria will go on to receive FPI-1966.

FUSN

Fusion Pharma Reports FDA Clearance Of Investigational New Drug Application For FPI-1966 For Treatment Of Head, Neck, Bladder Cancers Expressing Fibroblast Growth Factor 3

Shares of Orion Gr Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ORN#NYSE">ORN</a>) were flat after the company reported Q2 results.
<h2>Quarterly Results</h2>
Earnings per share increased 25.00% over the past year to $0.05, which missed the estimate of $0.08.
Revenue of $145,875,000 decreased by 20.60% from the same period last year, which missed the estimate of $168,950,000.
<h2>Outlook</h2>
Earnings guidance hasn&#39;t been issued by the company for now.
Revenue guidance hasn&#39;t been issued by the company for now.
<h2>Price Action</h2>
52-week high: $6.67
Company&#39;s 52-week low was at $2.46
Price action over last quarter: Up 7.39%
<h2>Company Description</h2>
Orion Group Holdings Inc is a specialty construction company serving the infrastructure, industrial, and building sectors, providing services both on and off the water in the continental United States, Alaska, Canada and the Caribbean Basin through its marine segment and its concrete segment. Its marine segment provides construction and dredging services relating to marine transportation facility construction, marine pipeline construction, marine environmental structures, dredging of waterways, channels and ports, environmental dredging, design, and specialty services. Its concrete segment provides turnkey concrete construction services including pour and finish, dirt work, layout, forming, rebar, and mesh across the light commercial, structural and other associated business areas.

Recap: Orion Gr Hldgs Q2 Earnings

LendingClub (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LC#NYSE">LC</a>) reported quarterly earnings of $0.56 per share which beat the analyst consensus estimate of $(0.43) by 230.23 percent. This is a 193.33 percent increase over losses of $(0.60) per share from the same period last year. The company reported quarterly sales of $204.40 million which beat the analyst consensus estimate of $134.55 million by 51.91 percent. This is a 365.93 percent increase over sales of $43.87 million the same period last year.

LendingClub Q2 EPS $0.56 Beats $(0.43) Estimate, Sales $204.40M Beat $134.55M Estimate

Dividends

Goosehead Insurance Declares Special Dividend Of $60M

Orion Group Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ORN#NYSE">ORN</a>) reported quarterly earnings of $0.05 per share which missed the analyst consensus estimate of $0.08 by 37.5 percent. This is a 25 percent increase over earnings of $0.04 per share from the same period last year. The company reported quarterly sales of $145.88 million which missed the analyst consensus estimate of $168.95 million by 13.66 percent. This is a 20.60 percent decrease over sales of $183.71 million the same period last year.

Orion Group Holdings Q2 EPS $0.05 Misses $0.08 Estimate, Sales $145.88M Miss $168.95M Estimate

Goosehead Insurance (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GSHD#NASDAQ">GSHD</a>) reported quarterly earnings of $0.13 per share which missed the analyst consensus estimate of $0.19 by 31.58 percent. This is a 31.58 percent decrease over earnings of $0.19 per share from the same period last year. The company reported quarterly sales of $38.17 million which beat the analyst consensus estimate of $37.66 million by 1.36 percent. This is a 27.57 percent increase over sales of $29.92 million the same period last year.

Goosehead Insurance Q2 EPS $0.13 Misses $0.19 Estimate, Sales $38.17M Beat $37.66M Estimate

PayPal Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PYPL#NASDAQ">PYPL</a>) reported quarterly earnings of $1.15 per share which beat the analyst consensus estimate of $1.13 by 1.77 percent. This is a 7.48 percent increase over earnings of $1.07 per share from the same period last year. The company reported quarterly sales of $6.24 billion which missed the analyst consensus estimate of $6.27 billion by 0.48 percent. This is a 18.61 percent increase over sales of $5.26 billion the same period last year.

PYPL

PayPal Holdings Q2 Adj. EPS $1.15 Beats $1.13 Estimate, Sales $6.24B Miss $6.27B Estimate -Reuters

BMRN

BioMarin Raises FY21 Total Revenue Guidance From $1.75B-$1.85B To $1.79B-$1.88B vs $1.82B Est.

Shares of Hologic (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOLX#NASDAQ">HOLX</a>) increased&nbsp;after the company reported Q3 results.
<h2>Quarterly Results</h2>
Earnings per share were up 77.33% year over year to $1.33, which beat the estimate of $1.12.
Revenue of $1,168,000,000 rose by 41.94% year over year, which beat the estimate of $1,040,000,000.
<h2>Outlook</h2>
Hologic Sees Q4 Adj. EPS $0.92-$1 vs $1.13 Estimate, Sales $1B-$1.04B vs $1.04B Est.
<h2>Conference Call Details</h2>
Date: Jul 28, 2021
Time: 04:30 PM
ET Webcast URL: <a href="https://edge.media-server.com/mmc/p/vw522xit" title="https://edge.media-server.com/mmc/p/vw522xit">https://edge.media-server.com/mmc/p/vw522xit</a>
<h2>Recent Stock Performance</h2>
Company&#39;s 52-week high was at $85.00
Company&#39;s 52-week low was at $56.81
Price action over last quarter: Up 8.88%
<h2>Company Overview</h2>
Hologic manufactures proprietary products for the healthcare needs of women. The company operates in five segments: breast health (44% of sales), diagnostics (39%) surgical (14%), and skeletal health (3%). While the company traditionally focused on breast health, the acquisition of Gen-Probe put greater emphasis on commercial diagnostics. The United States accounts for the largest portion of the firm&#39;s revenue (74%), followed by Europe (12%), Asia (9%), and other international markets (5%). Hologic is headquartered in Bedford, Massachusetts.

HOLX

Recap: Hologic Q3 Earnings

Stephanie Link, chief investment strategist and portfolio manager at Hightower Advisors, bought more General Electric Co (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/ge#NYSE">GE</a>) following Boeing Co&#39;s (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/ba#NYSE">BA</a>) earnings report, she said Wednesday on CNBC&#39;s &quot;Fast Money Halftime Report.&quot;
What Happened: Boeing reported quarterly earnings of 40 cents per share, which beat the estimate for a loss of 72 cents per share. The company reported quarterly revenue of $17 billion, which came in below the estimate of $17.78 billion.
Link told CNBC&nbsp;her General Electric buy is a &quot;derivative call on the Boeing recovery.&quot;
The numbers in the earnings report show that Boeing is clearly recovering from its COVID-19 pandemic decline, she said.
General Electric also reported a &quot;very solid second quarter yesterday,&quot; Link said.
On Tuesday, General Electric reported second-quarter earnings of 5 cents per share, which beat the estimate by a penny. The company reported quarterly revenue of $18.30 billion, which beat the estimate of $18.13 billion.&nbsp;
Related Link:&nbsp;<a href="https://www.benzinga.com/news/earnings/21/07/22166818/recap-general-electric-q2-earnings">Recap: General Electric Q2 Earnings</a>
What&#39;s Next: As Boeing recovers, General Electric will improve because the company is one of Boeing&#39;s largest engine suppliers, Link told CNBC.&nbsp;
Over the next six to 12 months, Link expects General Electric to be trading at $18 per share.&nbsp;
GE Price Action: General Electric has traded as high as $14.41 and as low as $5.93 over a 52-week period.
At the close Wednesday, the stock was up 0.38% at $13.13.
Photo by&nbsp;<a href="https://pixabay.com/users/2427999-2427999/?utm_source=link-attribution&amp;utm_medium=referral&amp;utm_campaign=image&amp;utm_content=3308222">2427999</a>&nbsp;from&nbsp;<a href="https://pixabay.com/?utm_source=link-attribution&amp;utm_medium=referral&amp;utm_campaign=image&amp;utm_content=3308222">Pixabay</a>.

Long Ideas

Media

Trading Ideas

Why This Investor Says A Boeing Recovery Could Send General Electric Stock Higher

Shares of FormFactor (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FORM#NASDAQ">FORM</a>) moved higher&nbsp;after the company reported Q2 results.
<h2>Quarterly Results</h2>
Earnings per share rose 9.09% year over year to $0.36, which beat the estimate of $0.33.
Revenue of $188,076,000 rose by 19.17% from the same period last year, which beat the estimate of $185,790,000.
<h2>Guidance</h2>
Earnings guidance hasn&#39;t been issued by the company for now.
Revenue guidance hasn&#39;t been issued by the company for now.
<h2>How To Listen To The Conference Call</h2>
Date: Jul 28, 2021
Time: 04:25 PM
ET Webcast URL: <a href="https://edge.media-server.com/mmc/p/ceecwoyo" title="https://edge.media-server.com/mmc/p/ceecwoyo">https://edge.media-server.com/mmc/p/ceecwoyo</a>
<h2>Technicals</h2>
52-week high: $52.39
Company&#39;s 52-week low was at $22.37
Price action over last quarter: down 7.27%
<h2>Company Profile</h2>
FormFactor Inc designs, develops, manufactures, sells, and supports advanced semiconductor probe card products. The company operates in two reportable segments namely Probe Cards Segment and the Systems Segment. Sales of probe cards and analytical probes are included in the Probe Cards Segment, while sales of probe stations and thermal sub-systems are included in the Systems Segment. Probe cards generate the maximum revenue from its operations. It offers multiple product lines which include analytical probes, probe stations, thermal sub-systems, and related services.

FORM

Recap: FormFactor Q2 Earnings

Management

XPO Logistics Announced The Appointment Of Ravi Tulsyan As Chief Financial Officer Effective September 2, 2021

Monarch Casino &amp; Resort (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MCRI#NASDAQ">MCRI</a>) reported quarterly earnings of $0.93 per share. This is a 487.5 percent increase over losses of $(0.24) per share from the same period last year. The company reported $97.70 million in sales this quarter. This is a 544.63 percent increase over sales of $15.16 million the same period last year.

MCRI

Monarch Casino & Resort Q2 EPS $0.93 Up From $(0.24) YoY, Sales $97.70M Up From $15.16M YoY

Churchill Downs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHDN#NASDAQ">CHDN</a>) reported quarterly earnings of $3.08 per share which beat the analyst consensus estimate of $2.52 by 22.22 percent. This is a 681.13 percent increase over losses of $(0.53) per share from the same period last year. The company reported quarterly sales of $515.10 million which beat the analyst consensus estimate of $478.63 million by 7.62 percent. This is a 178.28 percent increase over sales of $185.10 million the same period last year.

CHDN

Churchill Downs Q2 Adj. EPS $3.08 Beats $2.52 Estimate, Sales $515.10M Beat $478.63M Estimate

Marathon Petroleum Group Announced It Has Declared A Quarterly Dividend Of $0.58 Per Share On Common Stock Payable September 10, 2021 To Shareholders Of Record As The Close Of Business On August 18, 2021

&nbsp;

<h3>Gainers</h3>

<ul>
	<li>KemPharm (NASDAQ:<a class="ticker" href="/stock/KMPH#NASDAQ">KMPH</a>) stock moved upwards by 41.14% to $13.31 during Wednesday&#39;s regular session. KemPharm&#39;s stock is trading at a volume of 47.6 million shares as of 12:32 EST. This is 1957.84% of its average full-day volume over the last 100 days. The company&#39;s market cap stands at $250.8 million.</li>
	<li>Ovid Therapeutics (NASDAQ:<a class="ticker" href="/stock/OVID#NASDAQ">OVID</a>) stock rose 33.4% to $3.95. As of 12:32 EST, this security is trading at a volume of 102.7 million shares, making up 4170.99% of its average full-day volume over the last 100 days. The company&#39;s market cap stands at $250.4 million.</li>
	<li>Ocugen (NASDAQ:<a class="ticker" href="/stock/OCGN#NASDAQ">OCGN</a>) shares rose 22.71% to $11.78. As of 12:32 EST, Ocugen&#39;s stock is trading at a volume of 139.9 million, which is 161.71% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $2.2 billion.</li>
	<li>Castlight Health (NYSE:<a class="ticker" href="/stock/CSLT#NYSE">CSLT</a>) shares increased by 11.44% to $2.24. Trading volume for Castlight Health&#39;s stock is 2.5 million as of 12:32 EST. This is 228.61% of its average full-day volume over the last 100 days. The company&#39;s market cap stands at $353.0 million.</li>
	<li>Magenta Therapeutics (NASDAQ:<a class="ticker" href="/stock/MGTA#NASDAQ">MGTA</a>) stock rose 11.17% to $13.13. Magenta Therapeutics&#39;s stock is trading at a volume of 445.3K shares as of 12:32 EST. This is 162.75% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $634.2 million. The company&#39;s, Q4 earnings came out today.</li>
	<li>Satsuma Pharmaceuticals (NASDAQ:<a class="ticker" href="/stock/STSA#NASDAQ">STSA</a>) shares rose 11.04% to $6.94. Trading volume for Satsuma Pharmaceuticals&#39;s stock is 534.1K as of 12:32 EST. This is 109.34% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $120.9 million.</li>
</ul>

&nbsp;

&nbsp;

<h3>Losers</h3>

&nbsp;

<ul>
	<li>Vir Biotechnology (NASDAQ:<a class="ticker" href="/stock/VIR#NASDAQ">VIR</a>) shares fell 33.0% to $38.69 during Wednesday&#39;s regular session. Trading volume for Vir Biotechnology&#39;s stock is 4.1 million as of 12:32 EST. This is 259.48% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $4.9 billion. The company&#39;s, Q4 earnings came out 4 days ago.</li>
	<li>Genesis Healthcare (NYSE:<a class="ticker" href="/stock/GEN#NYSE">GEN</a>) shares decreased by 30.7% to $0.56. Genesis Healthcare&#39;s stock is trading at a volume of 18.0 million shares as of 12:32 EST. This is 527.87% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $93.7 million.</li>
	<li>Portage Biotech (NASDAQ:<a class="ticker" href="/stock/PRTG#NASDAQ">PRTG</a>) stock declined by 13.0% to $31.32. As of 12:32 EST, Portage Biotech&#39;s stock is trading at a volume of 1.2K, which is 20.13% of its average full-day volume over the last 100 days.</li>
	<li>Sensus Healthcare (NASDAQ:<a class="ticker" href="/stock/SRTS#NASDAQ">SRTS</a>) shares decreased by 11.56% to $4.36. As of 12:32 EST, Sensus Healthcare&#39;s stock is trading at a volume of 253.5K, which is 51.68% of its average full-day volume over the last 100 days. The company&#39;s market cap stands at $71.9 million. The company&#39;s, Q4 earnings came out 4 days ago.</li>
	<li>Windtree Therapeutics (NASDAQ:<a class="ticker" href="/stock/WINT#NASDAQ">WINT</a>) stock fell 10.94% to $4.4. Trading volume for Windtree Therapeutics&#39;s stock is 112.6K as of 12:32 EST. This is 260.77% of its average full-day volume over the last 100 days. The company&#39;s market cap stands at $74.4 million.</li>
	<li>ASLAN Pharmaceuticals (NASDAQ:<a class="ticker" href="/stock/ASLN#NASDAQ">ASLN</a>) stock fell 10.56% to $3.85. As of 12:32 EST, ASLAN Pharmaceuticals&#39;s stock is trading at a volume of 5.4 million, which is 314.48% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $221.7 million.</li>
</ul>

&nbsp;

&nbsp;

Intraday Update

Markets

Movers

12 Health Care Stocks Moving In Wednesday's Intraday Session

Portage Biotech Inc. (NASDAQ:<a class="ticker" href="/stock/PRTG#NASDAQ">PRTG</a>) (CSE:<a class="ticker" href="/stock/PBT#CSE">PBT</a>) (&quot;Portage&quot; or the &quot;Company&quot;), a clinical-stage immuno-oncology company focused on the development of therapies and treatments targeting cancer treatment resistance, today announced that the first patient has been dosed in the Phase 1 portion of the PRECIOUS-01 open-label, dose-escalation and expansion clinical trial assessing the safety, tolerability, efficacy and dosing of PORT-3 in the treatment of cancer.

Biotech

General

Portage Biotech Doses First Patient In PRECIOUS-01 Study Of PORT-3 For Treatment Of NY-ESO-1 Positive Solid Tumors

Portage Biotech Highlights Safety And Survival Data From Intensity Therapeutics' IT-01 Study Of INT230-6 At ASCO 2021 Annual Meeting

Here&#39;s a roundup of top developments in the biotech space over the last 24 hours.

<h3>Scaling The Peaks</h3>

(Biotech Stocks Hitting 52-week Highs June 17)

<ul>
	<li>10x Genomics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TXG#NASDAQ">TXG</a>)</li>
	<li>Bio-Techne Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TECH#NASDAQ">TECH</a>)</li>
	<li>Citius Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTXR#NASDAQ">CTXR</a>)</li>
	<li>Clearside Biomedical, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLSD#NASDAQ">CLSD</a>)</li>
	<li>Kindred Biosciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KIN#NASDAQ">KIN</a>)</li>
	<li>LeMaitre Vascular, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LMAT#NASDAQ">LMAT</a>)</li>
	<li>Natus Medical Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTUS#NASDAQ">NTUS</a>)</li>
	<li>NovoCure Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVCR#NASDAQ">NVCR</a>)</li>
	<li>Portage Biotech Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRTG#NASDAQ">PRTG</a>)</li>
	<li>Protagonist Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTGX#NASDAQ">PTGX</a>)</li>
	<li>Psychemedics Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PMD#NASDAQ">PMD</a>)</li>
	<li>Sesen Bio, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SESN#NASDAQ">SESN</a>)</li>
	<li>West Pharmaceutical Services, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WST#NYSE">WST</a>)</li>
	<li>Zoetis Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZTS#NYSE">ZTS</a>)</li>
</ul>

<h3>Down In The Dumps</h3>

(Biotech Stocks Hitting 52-week Lows June 17)

<ul>
	<li>4D Molecular Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FDMT#NASDAQ">FDMT</a>)</li>
	<li>AbCellera Biologics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABCL#NASDAQ">ABCL</a>)</li>
	<li>Alzamend Neuro, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALZN#NASDAQ">ALZN</a>) (IPOed Tuesday)</li>
	<li>Atreca, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCEL#NASDAQ">BCEL</a>)</li>
	<li>Cullinan Oncology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGEM#NASDAQ">CGEM</a>)</li>
	<li>Dyadic International, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DYAI#NASDAQ">DYAI</a>)</li>
	<li>Inhibikase Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IKT#NASDAQ">IKT</a>)</li>
	<li>MediciNova, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNOV#NASDAQ">MNOV</a>)</li>
	<li>Pharming Group N.V. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PHAR#NASDAQ">PHAR</a>)</li>
	<li>Spruce Biosciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPRB#NASDAQ">SPRB</a>)</li>
	<li>Vertex Pharmaceuticals Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>)</li>
	<li>Yumanity Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/YMTX#NASDAQ">YMTX</a>)</li>
</ul>

<h3>Stocks In Focus</h3>

<h3>Athira Pharma CEO Placed On Temporary Leave Over Impropriety In Doctoral Research Program</h3>

Athira Pharma, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATHA#NASDAQ">ATHA</a>) said its board has determined to place its CEO Leen Kawas on temporary leave, pending a review of actions stemming from doctoral research she conducted while at Washington State University.

The company also said Mark Litton, in his capacity as chief operating officer, has assumed day-to-day leadership responsibilities for the company, effective immediately.

The stock plunged 34.21% to $6.24 in after-hours trading.

<h3>Orphazyme Issued Complete Response Letter For Rare Neurodegenerative Disease Drug</h3>

Orphazyme A/S (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ORPH#NASDAQ">ORPH</a>) <a href="https://www.benzinga.com/general/biotech/21/06/21621339/orphazyme-wild-party-at-risk-as-fda-rejects-its-rare-neurodegenerative-disease-drug">said </a> its new drug application, seeking approval for arimoclomol as a treatment option for Niemann-Pick disease type C (NPC), was turned down with a complete response letter.

The CRL issued by the FDA seeks additional qualitative and quantitative evidence to substantiate further the validity and interpretation of the 5-domain NPC Clinical Severity Scale, in particular the swallow domain.

More importantly, the FDA has sought additional data to strengthen evidence beyond the single phase 2/3 clinical trial to support the benefit-risk assessment of the NDA.

The stock was plunging 54.60% to $6.61.

Related Link: <a href="https://www.benzinga.com/general/biotech/21/05/21351378/the-week-ahead-in-biotech-asco-presentations-front-and-center-fda-decisions-due-for-scynexis-limi"> Attention Biotech Investors: Mark Your Calendar For June PDUFA Dates </a>

<h3>Bristol-Myers Squibb In-licenses Eisai&#39;s Antibody-drug Conjugate For Solid Tumors</h3>

Eisai Co., Ltd. (OTC:<a class="ticker" href="https://www.benzinga.com/stock/ESALY#OTC">ESALY</a>) and Bristol-Myers Squibb Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) announced an exclusive global strategic collaboration agreement for the co-development and co-commercialization of MORAb-202, an antibody drug conjugate.

Eisai is currently investigating MORAb-202 in FR&alpha;-positive solid tumors, inclusive of endometrial, ovarian, lung and breast cancers, in two studies: a Phase 1 clinical study in Japan and a Phase 1/2 clinical study in the U.S. The companies are planning to move into the registrational stage of development for this asset as early as next year.

Under the financial terms of the agreement, Bristol Myers Squibb will pay $650 million to Eisai, including $200 million as payment toward Eisai research and development expenses. Eisai is also entitled to receive up to $2.45 billion in potential future development, regulatory, and commercial milestones.

Bristol Myers Squibb will also pay Eisai a royalty on sales outside of the collaboration territories.

<h3>Geron Announces Publication of Positive Phase 2 Data For Imetelstat In Myelofibrosis Study</h3>

Geron Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GERN#NASDAQ">GERN</a>) announced the publication of data from the IMbark Phase 2 clinical trial in the Journal of Clinical Oncology, highlighting the clinical benefits of imetelstat observed in myelofibrosis study, including symptom response and overall survival, as well as the evidence of disease-modifying activity from biomarker and bone marrow fibrosis assessments. 
The 9.4 mg/kg dose of imetelstat every three weeks demonstrated clinical benefits in symptom response rate, with an acceptable safety profile for this poor-risk JAKi relapsed/refractory MF patient population. Biomarker and bone marrow assessments suggested selective effects on the malignant clone.

The stock jumped 19.86% to $1.69 in after-hours trading.

<h3>BioNTech Commences Mid-stage Study of Vaccine Candidate Against Skin Cancer</h3>

BioNTech SE (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNTX#NASDAQ">BNTX</a>) said the first patient has been treated in its BNT111 Phase 2 cancer vaccine trial. The study is evaluating the company&#39;s therapeutic cancer vaccine candidate BNT111 in combination with Regeneron, Pharmaceuticals, Inc.&#39;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGNP#NASDAQ">REGNP</a>) Libtayo in patients with anti-PD1-refractory/relapsed unresectable Stage III or IV melanoma.

BNT111 is the lead product candidate from BioNTech&#39;s FixVac platform that targets a fixed combination of mRNA-encoded, tumor-associated antigens with the objective of triggering a strong and precise immune response against cancer and is fully owned by BioNTech.

The stock was up 0.15% at $214.53 in premarket trading Friday.

<h3>Pharming Announces Appointment of Chief Medical Officer and Chief Scientific Officer</h3>

Pharming Group N.V. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PHAR#NASDAQ">PHAR</a>) announced the appointment of Anurag Relan as chief medical officer, effective immediately, and Robert Friesen as chief scientific officer, effective from Aug. 1.

Bruno Giannetti, who held the post of chief medical officer, has announced his retirement from the executive committee.

<h3>Galera Gains On Insider Buying</h3>

Galera Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRTX#NASDAQ">GRTX</a>) shares rose after a series of filings revealed its senior management team exercising options to buy shares in the company.

The stock gained 4.39% to $9.51 in after-hours trading.

<h3>Codexis Raises FY21 Revenue Guidance On Receipt of Binding Orders For Enzyme Products</h3>

Codexis, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDXS#NASDAQ">CDXS</a>) said it is raising its 2021 guidance for total revenues to a range of $89 million to $93 million, up from previous guidance of $82 million to $85 million. Analysts, on average, estimate revenues of $83.74 million for the year.

This follows the receipt of a binding purchase order for up to $13.9 million of a proprietary high performance enzyme product from an undisclosed global pharmaceutical company.

The company also raised its product and gross margin guidance.

The stock added 6.67% to $20.95 in after-hours trading.

<h3>On The Radar</h3>

<h3>IPO</h3>

atai Life Sciences B.V., a clinical-stage biopharma developing treatments for mental health disorders, priced its upsized initial public offering of 15 million shares of its common shares at $15, the upper bound of the estimated price range. All common shares to be sold in the proposed offering will be sold by atai.

The shares of the German pyschedelics company are expected to begin trading on the Nasdaq under the ticker symbol &quot;ATAI.&quot;

Codex DNA, Inc., creators of the BioXp system, a fully automated benchtop instrument that enables numerous synthetic biology workflows, priced its IPO of 6.67 million shares of its common stock at a public offering price of $16 per share. All of the shares are being offered by Codex DNA.

The gross proceeds of the offering are expected to be $106.7 million. The shares are expected to begin trading on the Nasdaq under the ticker symbol &quot;DNAY.&quot;

Cyteir Therapeutics, Inc., a company focused on the development of next-generation synthetically lethal therapies for cancer, priced its IPO of 7.4 million shares at $18 per share. All of the shares are being offered by Cyteir. The shares are scheduled to begin trading on the Nasdaq under the ticker symbol &quot;CYT.&quot;

The gross proceeds of the offering are expected to be approximately $133 million.

Ambrx, a clinical stage biopharma using an expanded genetic code technology platform to discover and develop engineered precision biologics, priced its IPO of 7 million ADSs, each representing seven ordinary shares, at $18 per ADS.

The total gross proceeds to Ambrx from the offering are expected to be $126 million All of the ADSs are being offered by Ambrx. The shares are expected to begin trading on the NYSE under the ticker symbol &quot;AMAM.&quot;

Century Therapeutics, a biotech developing induced pluripotent stem cell-derived cell therapies in immuno-oncology, priced its IPO of 10.55 million shares of its common stock at a $20 per share. All of the shares of common stock are being offered by Century.

The gross proceeds from the offering are expected to be $211.0 million. The shares are expected to begin trading on the Nasdaq under the ticker symbol &quot;IPSC.&quot;

Penny Stocks

Small Cap

IPOs

Pre-Market Outlook

The Daily Biotech Pulse: Orphazyme Falters At FDA, Athira's CEO Placed On Temporary Leave, 5 IPOs

<h3>Gainers</h3>

<ul>
	<li>Alfi, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALF#NASDAQ">ALF</a>) shares jumped 108.9% to settle at $16.29 on Tuesday following exclusive Benzinga reporting the company will buyback up to $2 million of its stock. Company CEO told Benzinga ALFI&#39;s stock is &quot;undervalued based on pipeline projections and identified opportunity.&quot;</li>
	<li>County Bancorp, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICBK#NASDAQ">ICBK</a>) shares climbed 47.3% to close at $34.45 on Tuesday. Nicolet Bankshares reported a deal to buy County Bancorp.</li>
	<li>Idera Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IDRA#NASDAQ">IDRA</a>) jumped 41.1% to close at $1.58 after it was disclosed in a Form4 filing the company COO Daniel Soland purchased 50,000 shares of the company stock at an average price of $1.19.</li>
	<li>3D Systems Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DDD#NYSE">DDD</a>) climbed 27.7% to close at $36.87 after the company and CollPlant announced an agreement for a 3D bioprinted regenerative soft tissue matrix for use in breast reconstruction procedures.</li>
	<li>SilverSun Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SSNT#NASDAQ">SSNT</a>) gained 24.3% to settle at $10.50 after the company announced a cash dividend.</li>
	<li>Gold Royalty Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GROY#NYSE">GROY</a>) jumped 22.4% to settle at $5.53. Gold Royalty announced inclusion in Vaneck Vectors Junior Gold Miners ETF. HC Wainwright &amp; Co. maintained Gold Royalty with a Buy and raised the price target from $7.25 to $7.5.</li>
	<li>Beyond Air, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XAIR#NASDAQ">XAIR</a>) shares jumped 21% to close at $6.17 after company director Robert Carey disclosed the purchase of 350K shares of the company&#39;s stock at an average price of $5.36.</li>
	<li>SharpSpring, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHSP#NASDAQ">SHSP</a>) shares gained 19.8% to close at $16.91 after the company agreed to be acquired by Constant Contact for $240 million.</li>
	<li>Atossa Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATOS#NASDAQ">ATOS</a>) climbed 19.2% to close at $7.02.</li>
	<li>Digital Brands Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DBGI#NASDAQ">DBGI</a>) surged 18.9% to settle at $4.22.</li>
	<li>Westwater Resources, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WWR#NYSE">WWR</a>) rose 17.9% to close at $5.27 after the company announced it is bringing a graphite-processing plant and jobs to Alabama.</li>
	<li>Engine Media Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GAME#NASDAQ">GAME</a>) surged 15.3% to close at $10.81.</li>
	<li>Plug Power Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLUG#NASDAQ">PLUG</a>) gained 14% to close at $34.02 after the company reported Q1 results.</li>
	<li>Sally Beauty Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SBH#NYSE">SBH</a>) surged 13.6% to settle at $22.08 after multiple firms upgraded the stock and announced their price targets, respectively.</li>
	<li>Full Truck Alliance Co. Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/YMM#NYSE">YMM</a>) surged 13.2% to settle at $21.50 after the company priced 82.5 million American depositary shares (ADS) at $19 per ADS in its initial public offering. One ADS represents 20 ordinary shares.</li>
	<li>CollPlant Biotechnologies Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLGN#NASDAQ">CLGN</a>) rose 12.6% to close at $20.61. 3D Systems and Collplant Biotechnologies announced they have signed a co-development agreement for a 3D bioprinted regenerative soft tissue matrix for use in breast reconstruction procedures in combination with an implant.</li>
	<li>Clover Health Investments, Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLOV#NASDAQ">CLOV</a>) gained 12.4% to close at $12.63.</li>
	<li>Vinco Ventures, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BBIG#NASDAQ">BBIG</a>) shares gained 11.6% to settle at $4.99 after surging around 12% on Monday.</li>
	<li>Splunk Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPLK#NASDAQ">SPLK</a>) gained 11.3% to close at $139.61 after the company announced that technology-focused private equity firm Silver Lake would make a $1 billion investment in senior convertible notes to support its continued business transformation.</li>
	<li>Onion Global Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OG#NYSE">OG</a>) gained 10.7% to close at $4.26. Onion Global, earlier during the month, reported Q1 results.</li>
	<li>Sanderson Farms, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAFM#NASDAQ">SAFM</a>) surged 10.3% to close at $183.78 on a report suggesting the company is exploring a sale. Also, JP Morgan maintained an Overweight rating and raised its price target from $175 to $198.</li>
	<li>Tupperware Brands Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TUP#NYSE">TUP</a>) climbed 10% to settle at $22.38 after the company announced the prepayment of term loan debt and $250 million share repurchase authorization.</li>
	<li>GameStop Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GME#NYSE">GME</a>) climbed 10% to settle at $220.40 as the company said it has completed at-the-market equity offering program.</li>
	<li>Adial Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADIL#NASDAQ">ADIL</a>) gained 9.1% to settle at $3.13 after the company announced plans to enter genetic testing market following allowance of U.S. patent for genetic diagnostic test.</li>
	<li>Auddia Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AUUD#NASDAQ">AUUD</a>) rose 9% to close at $3.02 after the company reported major technology advancements in Artificial Intelligence with new audio content processing methodology.</li>
	<li>Score Media and Gaming Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SCR#NASDAQ">SCR</a>) gained 9% to close at $24.28.</li>
	<li>Paymentus Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PAY#NYSE">PAY</a>) gained 8.1% to close at $32.63.</li>
	<li>DLocal Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DLO#NASDAQ">DLO</a>) shares rose 5% to close at $40.50.</li>
</ul>

&nbsp;

<a href="https://www.benzinga.com/investing/best-penny-stocks/">Check out these big penny stock gainers and losers</a>

<h3>Losers</h3>

<ul>
	<li>New Concept Energy, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GBR#NYSE">GBR</a>) shares fell 37.3% to close at $5.89 on Tuesday after climbing over 73% on Monday.</li>
	<li>Torchlight Energy Resources, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRCH#NASDAQ">TRCH</a>) shares dropped 29.4% to settle at $7.00 after the company announced an amendment to its At-The-Market offering deal with Roth Capital. The offering was raised from $100 million to $250 million.</li>
	<li>Portage Biotech Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRTG#NASDAQ">PRTG</a>) fell 14.6% to close at $33.91.</li>
	<li>Prometheus Biosciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RXDX#NASDAQ">RXDX</a>) shares declined 14.1% to close at $22.14. Prometheus Biosciences recently said it achieved milestone payment of $10 million from Dr. Falk Pharma GmbH.</li>
	<li>Cassava Sciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAVA#NASDAQ">SAVA</a>) fell 13.5% to close at $77.63. Cassava Sciences announced it has selected Premier Research International as its clinical research organization to help conduct the Phase 3 clinical program for simufilam in Alzheimer&#39;s disease. Consistent with previous guidance, Cassava Sciences said it plans to initiate this Phase 3 program in the second half of 2021.</li>
	<li>PEDEVCO Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PED#NYSE">PED</a>) shares dipped 12.7% to settle at $1.45 after surging 15% on Monday.</li>
	<li>Annovis Bio, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ANVS#NYSE">ANVS</a>) fell 12.3% to close at $84.25.</li>
	<li>Verastem, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VSTM#NASDAQ">VSTM</a>) dropped 11.8% to settle at $4.28.</li>
	<li>Petros Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTPI#NASDAQ">PTPI</a>) dipped 11.4% to close at $3.11.</li>
	<li>MicroVision, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MVIS#NASDAQ">MVIS</a>) fell 10.6% to settle at $17.49 after the company announced a $140 million at-the-market equity offering.</li>
	<li>JinkoSolar Holding Co., Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JKS#NYSE">JKS</a>) tumbled 9.9% to close at $37.14.</li>
	<li>Impel NeuroPharma, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMPL#NASDAQ">IMPL</a>) dropped 9.6% to close at $8.18.</li>
	<li>Ebang International Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EBON#NASDAQ">EBON</a>) fell 8.1% to close at $3.08 amid a drop in Bitcoin.</li>
	<li>Barnwell Industries, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRN#NYSE">BRN</a>) fell 7.8% to close at $2.97.</li>
	<li>The9 Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NCTY#NASDAQ">NCTY</a>) dropped 6.9% to close at $13.56 after dropping 12% on Monday.</li>
	<li>Focus Financial Partners Inc.. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FOCS#NASDAQ">FOCS</a>) shares fell 5.9% to close at $51.19 after the company reported the pricing of its underwritten secondary offering of 7,417,929 shares of its Class A common stock.</li>
</ul>

44 Biggest Movers From Yesterday

Offerings

Portage Biotech Inc. Announces Proposed Offering of Ordinary Shares; No Terms Disclosed

<h3>Gainers</h3>

<ul>
	<li>Marin Software Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRIN#NASDAQ">MRIN</a>) rose 43.3% to $2.45 in pre-market trading after the company announced it has added the ability to manage Instacart Ads to its flagship MarinOne platform.</li>
	<li>India Globalization Capital, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IGC#NYSE">IGC</a>) rose 37.8% to $2.04 in pre-market trading. IGC said it has completed the final Cohort of its Phase 1 Clinical trial on Alzheimer&rsquo;s patients.</li>
	<li>GTT Communications, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GTT#NYSE">GTT</a>) rose 37.5% to $3.41 in pre-market trading after surging over 13% on Wednesday.</li>
	<li>DHI Group, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHX#NYSE">DHX</a>) shares rose 17.6% to $3.28 in pre-market trading after the company announced it will add $12 million to its stock buyback, increasing the overall buyback to $20 million.</li>
	<li>Arcus Biosciences, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RCUS#NYSE">RCUS</a>) shares rose 15% to $26.90 in pre-market trading after the company disclosed data from the first interim analysis of the three-arm randomized Phase 2 ARC-7 study.</li>
	<li>Applied Genetic Technologies Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGTC#NASDAQ">AGTC</a>) shares rose 14.2% to $4.76 in pre-market trading after the company announced plans to release 12-month data for adult patients and low-dose pediatric patients in its Phase 1/2 clinical Achromatopsia trials on Thursday, June 24, 2021.</li>
	<li>iBio, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IBIO#NYSE">IBIO</a>) rose 12.2% to $1.75 in pre-market trading after the company reported Q3 results.</li>
	<li>Orphazyme A/S (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ORPH#NASDAQ">ORPH</a>) rose 10% to $8.18 in pre-market trading. Orphazyme, which recently faced a regulatory setback, said the Goldman Sachs Group briefly increased its stake in Orphazyme above 5%.</li>
	<li>Uxin Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UXIN#NASDAQ">UXIN</a>) rose 8.8% to $4.07 in pre-market trading after gaining over 7% on Wednesday.</li>
	<li>Franklin Street Properties Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FSP#NYSE">FSP</a>) rose 8.4% to $5.69 in pre-market trading after the company reported a $50-million buyback.</li>
	<li>Sprinklr, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CXM#NYSE">CXM</a>) shares rose 8.2% to $19.04 in pre-market trading. Sprinklr shares gained 10% on Wednesday after the company priced its IPO at $16 per share.</li>
	<li>Tower Semiconductor Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSEM#NASDAQ">TSEM</a>) rose 7.7% to $29.42 in pre-market trading. STMicroelectronics and Tower Semiconductor announced an agreement by which STMicroelectronics will bring Tower Semiconductor on board 300mm analog and power fab under construction in Italy.</li>
	<li>Sundial Growers Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNDL#NASDAQ">SNDL</a>) rose 6% to $1.06 in pre-market trading after surging over 12% on Wednesday.</li>
	<li>Clover Health Investments, Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLOV#NASDAQ">CLOV</a>) rose 5.8% to $14.63 in pre-market trading after gaining around 10% on Wednesday.</li>
	<li>Neptune Wellness Solutions Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEPT#NASDAQ">NEPT</a>) shares rose 5.7% to $1.27 in pre-market trading after declining 4% on Wednesday.</li>
	<li>Moxian, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MOXC#NASDAQ">MOXC</a>) rose 5.4% to $21.17 in pre-market trading after jumping 22% on Wednesday.</li>
	<li>Property Solutions Acquisition Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSAC#NASDAQ">PSAC</a>) rose 5.4% to $15.70 in pre-market trading after climbing over 8% on Wednesday.</li>
	<li>FTAC Olympus Acquisition Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTOC#NASDAQ">FTOC</a>) shares rose 5% to $10.91 in pre-market trading. FTAC Olympus Acquisition&rsquo;s shareholders approved proposed business combination with Payoneer.</li>
	<li>Steelcase Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SCS#NYSE">SCS</a>) rose 3.2% to $15.00 in pre-market trading after the company reported better-than-expected Q1 results and issued Q2 guidance above estimates.</li>
</ul>

 
Find out what&#39;s going on in today&#39;s market and bring any questions you have to <a href="http://premarket.benzinga.com/pre-market-show/">Benzinga&#39;s PreMarket Prep</a>.

<a href="https://www.benzinga.com/investing/best-penny-stocks/">Check out these big penny stock gainers and losers</a>

<h3>Losers</h3>

<ul>
	<li>Portage Biotech Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRTG#NASDAQ">PRTG</a>) fell 24.7% to $26.20 in pre-market trading after the company reported a proposed offering of ordinary shares.</li>
	<li>Daqo New Energy Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DQ#NYSE">DQ</a>) fell 6.5% to $54.32 in pre-market trading after gaining around 3% on Wednesday.</li>
	<li>Talos Energy Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TALO#NYSE">TALO</a>) shares fell 6.3% to $17.48 in pre-market trading after the company reported the pricing of secondary public offering of common stock.</li>
	<li>ReTo Eco-Solutions, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RETO#NASDAQ">RETO</a>) fell 5.3% to $1.25 in pre-market trading. ReTo Eco-Solutions shares gained around 13% on Wednesday after the company announced a $43.7 million project to conduct annual iron ore tailings treatment.</li>
	<li>Adial Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADIL#NASDAQ">ADIL</a>) shares fell 4.8% to $2.80 in pre-market trading after dropping 6% on Wednesday. The company recently announced plans to enter genetic testing market following allowance of U.S. patent for genetic diagnostic test.</li>
	<li>Tenax Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TENX#NASDAQ">TENX</a>) shares fell 4% to $2.00 in pre-market trading after gaining around 10% on Wednesday.</li>
</ul>

25 Stocks Moving in Thursday's Pre-Market Session

&nbsp;

<h3>Gainers</h3>

<ul>
	<li>Aravive (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARAV#NASDAQ">ARAV</a>) stock moved upwards by 21.61% to $6.47 during Thursday&#39;s pre-market session. The company&#39;s market cap stands at $131.9 million.</li>
	<li>Arcus Biosciences (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RCUS#NYSE">RCUS</a>) stock rose 19.61% to $27.99. The company&#39;s market cap stands at $1.9 billion.</li>
	<li>Pieris Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PIRS#NASDAQ">PIRS</a>) stock moved upwards by 16.1% to $4.11. The market value of their outstanding shares is at $239.6 million.</li>
	<li>Passage Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PASG#NASDAQ">PASG</a>) shares moved upwards by 15.55% to $15.9. The market value of their outstanding shares is at $858.2 million.</li>
	<li>Alterity Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATHE#NASDAQ">ATHE</a>) stock increased by 13.74% to $1.49. The market value of their outstanding shares is at $51.7 million.</li>
	<li>Orphazyme (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ORPH#NASDAQ">ORPH</a>) stock moved upwards by 9.81% to $8.17. The company&#39;s market cap stands at $285.5 million.</li>
</ul>

&nbsp;

&nbsp;

<h3>Losers</h3>

&nbsp;

<ul>
	<li>Portage Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRTG#NASDAQ">PRTG</a>) shares declined by 28.74% to $24.8 during Thursday&#39;s pre-market session.</li>
	<li>Biogen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIIB#NASDAQ">BIIB</a>) shares decreased by 7.76% to $343.06. The market value of their outstanding shares is at $51.6 billion.</li>
	<li>Adial Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADIL#NASDAQ">ADIL</a>) shares decreased by 7.49% to $2.72. The market value of their outstanding shares is at $49.5 million.</li>
	<li>Bellerophon Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLPH#NASDAQ">BLPH</a>) stock fell 5.64% to $5.02. The market value of their outstanding shares is at $47.7 million.</li>
	<li>Alpine Immune Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALPN#NASDAQ">ALPN</a>) stock decreased by 4.51% to $8.87. The market value of their outstanding shares is at $212.1 million.</li>
	<li>Satsuma Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STSA#NASDAQ">STSA</a>) stock fell 3.78% to $6.05. The company&#39;s market cap stands at $190.8 million.</li>
</ul>

&nbsp;

&nbsp;

12 Health Care Stocks Moving In Thursday's Pre-Market Session

Portage Biotech Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRTG#NASDAQ">PRTG</a>) (&quot;Portage&quot; or the &quot;Company&quot;) a clinical-stage immuno-oncology company focused on the development of therapies and treatments targeting cancer treatment resistance, today announced that it has priced its previously announced underwritten public offering of 1,000,000 ordinary shares. The public offering price of each ordinary share is&nbsp;$23.00. In addition, Portage has granted the underwriters a 30-day option to purchase up to an additional 150,000 ordinary shares at the public offering price, less underwriting discounts and commissions. This offering is expected to close on or about June 28, 2021, subject to satisfaction of customary closing conditions.

Cantor Fitzgerald &amp; Co. and Oppenheimer &amp; Co. Inc. are acting as book-running managers for the offering. B.Riley Securities, Inc. is acting as the lead manager for the offering.

Portage intends to use the gross proceeds of&nbsp;$23,000,000&nbsp;before deducting underwriting discounts and offering expenses (without giving effect to any exercise of the underwriters&#39; option to purchase additional ordinary shares, if any), for the acceleration of its PORT-2 and PORT-3 clinical programs, to prepare the next products to enter the clinic, and for working capital and other general corporate purposes.

The ordinary shares are offered pursuant to a shelf registration statement on Form F-3 (File No. 333-253468), including a base prospectus, filed by Portage on February 24, 2021 and declared effective by the Securities and Exchange Commission, or the SEC, on March 8, 2021. The offering will be made only by means of a prospectus. A preliminary prospectus supplement related to the offering was filed with the SEC on June 23, 2021 and is available on the SEC&#39;s website at&nbsp;<a href="https://www.newsfilecorp.com/redirect/3eeO5CaXy8">www.sec.gov</a>. A final prospectus supplement related to the offering will be filed with the SEC and will be available on the SEC&#39;s website. Copies of the final prospectus supplement and the accompanying prospectus relating to the offering may also be obtained from the offices of: Cantor Fitzgerald &amp; Co., Attention: Capital Markets, 499 Park Ave., 4th Floor, New York, New York 10022, or by email at&nbsp;<a href="mailto:prospectus@cantor.com">prospectus@cantor.com</a>; or Oppenheimer &amp; Co. Inc., Attention: Syndicate Prospectus Department, 85 Broad Street, 26th Floor, New York, New York 10004, by telephone at 212-667-8055, or by email at&nbsp;<a href="mailto:EquityProspectus@opco.com">EquityProspectus@opco.com</a>.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such state or jurisdiction.

Portage Biotech Announces Pricing Of Public Offering Of 1M Ordinary Shares At $23/Share

Following the market opening Thursday, the Dow traded up 0.76% to 34,130.38 while the NASDAQ rose 0.75% to 14,379.10. The S&amp;P also rose, gaining 0.54% to 4,264.62.

The U.S. has the highest number of coronavirus cases and deaths in the world, reporting a total of 33,577,710 cases with around 602,830 deaths. India confirmed a total of at least 30,082,770 cases and 391,980 deaths, while Brazil reported over 18,169,880 COVID-19 cases with 507,100 deaths. In total, there were at least 179,635,440 cases of COVID-19 worldwide with more than 3,892,810 deaths, according to data compiled by Johns Hopkins University.

 
Leading and Lagging Sectors

 
Health care shares rose by 1% on Thursday. Meanwhile, top gainers in the sector included Aravive, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARAV#NASDAQ">ARAV</a>), up 14%, and Arcus Biosciences, Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RCUS#NYSE">RCUS</a>), up 16%.

 
In trading on Thursday, energy shares fell 0.4%.

 
Top Headline

Accenture plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACN#NYSE">ACN</a>) reported stronger-than-expected results for its third quarter and raised its FY21 guidance.

Accenture reported quarterly earnings of $2.40 per share, exceeding analysts&rsquo; estimates of $2.23 per share. The company&rsquo;s quarterly sales came in at $13.30 billion, versus expectations of $12.80 billion.

Accenture said it now expects FY21 EPS of $8.71-$8.80, versus earlier guidance of $8.32-$8.50. The company also boosted its FY21 sales forecast from 6.5%-8.5% to 10%-11%.

&nbsp;

 
Equities Trading UP

 
Digital Brands Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DBGI#NASDAQ">DBGI</a>) shares shot up 27% to $5.18 after the company reported channel expansion into Amazon Marketplace.

 
Shares of SEMrush Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SEMR#NYSE">SEMR</a>) got a boost, shooting 20% to $24.26.

 
Miromatrix Medical Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MIRO#NASDAQ">MIRO</a>) shares were also up, gaining 23% to $11.05 after the company reported pricing of upsized initial public offering.

<a href="https://www.benzinga.com/movers">Check out these big movers of the day</a>

 
Equities Trading DOWN

Portage Biotech Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRTG#NASDAQ">PRTG</a>) shares tumbled 24% to $26.50 after the company reported pricing of public offering of 1 million ordinary shares at $23 per share.

Shares of Rite Aid Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RAD#NYSE">RAD</a>) were down 15% to $17.45 after the company reported weaker-than-expected Q1 sales.

iSpecimen Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISPC#NASDAQ">ISPC</a>) was down, falling 12% to $5.80. The company recently priced its IPO at $8 per share.

 
Commodities

 
In commodity news, oil traded down 0.1% to $73.06, while gold traded down 0.1% to $1,782.30.

 
Silver traded down 0.1% Thursday to $26.09 while copper fell 0.5% to $4.3080.

 
Euro zone

European shares were higher today. The eurozone&rsquo;s STOXX 600 gained 0.7%, the Spanish Ibex Index climbed 1.3% and the German DAX 30 gained 0.8%. Meanwhile, the London&rsquo;s FTSE 100 rose 0.3%, French CAC 40 climbed 1% and Italy&rsquo;s FTSE MIB surged 0.9%.

German Ifo Business Climate indicator increased 2.6% to 101.8 in June, while French manufacturing climate indicator came in unchanged at 107 in June. Spanish gross domestic product contracted 0.4% on quarter during the first three months of the year.

 
Economics

US durable goods orders rose 2.3% month-over-month in May.

 
The US economy expanded by an annualized 6.4% in the first quarter.

 
The US goods trade deficit increased to $88.1 billion in May versus a revised $85.7 billion gap in the prior month.

 
US initial jobless claims dropped to 411,000 in the week ending June 19th, versus a revised 418,000 in the prior period.

 
Wholesale inventories rose 1.1% to $707.5 billion in May.

 
The Energy Information Administration&rsquo;s weekly report on natural gas stocks in underground storage is scheduled for released at 10:30 a.m. ET.

 
Federal Reserve Bank of New York President John Williams is set to speak at 11:00 a.m. ET.

 
The Kansas City Fed manufacturing index for June will be released at 11:00 a.m. ET.

 
The Treasury is set to auction 4-and 8-week bills at 11:30 a.m. ET.

 
Dallas Fed President Robert Kaplan will speak at 1:00 p.m. ET.

 
St. Louis Fed President James Bullard is set to speak at 1:00 p.m. ET.

 
The Treasury will auction 7-year notes at 1:00 p.m. ET.

<a href="https://www.benzinga.com/calendar/economics/">Check out the full economic calendar here </a>

Eurozone

Commodities

Global

Mid-Morning Market Update: Markets Open Higher; Accenture Reports Upbeat Q3 Results

<h3>Gainers</h3>

<ul>
	<li>Marin Software Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRIN#NASDAQ">MRIN</a>) jumped 58% to $2.70 after the company announced it has added the ability to manage Instacart Ads to its flagship MarinOne platform.</li>
	<li>Miromatrix Medical Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MIRO#NASDAQ">MIRO</a>) shares jumped 50.1% to $13.51 after the company reported pricing of upsized initial public offering.</li>
	<li>Digital Brands Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DBGI#NASDAQ">DBGI</a>) shares jumped 44.2% to $5.90 after the company reported channel expansion into Amazon Marketplace.</li>
	<li>Kaleido Biosciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KLDO#NASDAQ">KLDO</a>) surged 26.4% to $8.84 on above-average volume.</li>
	<li>SEMrush Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SEMR#NYSE">SEMR</a>) gained 22.3% to $24.70.</li>
	<li>Pieris Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PIRS#NASDAQ">PIRS</a>) surged 21.1% to $4.2899 after the company announced it received Orphan Drug Designation for cinrebafusp alfa for the treatment of gastric cancer.</li>
	<li>Moxian, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MOXC#NASDAQ">MOXC</a>) gained 21% to $24.31 after jumping 22% on Wednesday.</li>
	<li>The Trade Desk, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTD#NASDAQ">TTD</a>) surged 18.5% to $77.52 mid strength in advertising technology stocks after Google announced it is delaying the phase-out of third-party cookies on Chrome until 2023.</li>
	<li>India Globalization Capital, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IGC#NYSE">IGC</a>) rose 15.5% to $1.71. IGC said it has completed the final Cohort of its Phase 1 Clinical trial on Alzheimer&rsquo;s patients.</li>
	<li>Arcus Biosciences, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RCUS#NYSE">RCUS</a>) shares climbed 13.9% to $26.65 after the company disclosed data from the first interim analysis of the three-arm randomized Phase 2 ARC-7 study.</li>
	<li>Compugen Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGEN#NASDAQ">CGEN</a>) gained 13.8% to $8.86. recently announced updated data from its Phase 1 dose-escalation and expansion study of COM701 as a monotherapy and in a dose-escalation combination study with Bristol-Myers Squibb&rsquo;s Opdivo (nivolumab).</li>
	<li>X Financial (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XYF#NYSE">XYF</a>) surged 13.4% to $10.96.</li>
	<li>Uxin Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UXIN#NASDAQ">UXIN</a>) rose 13.4% to $4.24 after gaining over 7% on Wednesday.</li>
	<li>Global-e Online Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLBE#NASDAQ">GLBE</a>) gained 12.4% to $62.00.</li>
	<li>Synchronoss Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNCR#NASDAQ">SNCR</a>) gained 12.3% to $2.7296.</li>
	<li>GTT Communications, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GTT#NYSE">GTT</a>) rose 11.8% to $2.77 after surging over 13% on Wednesday.</li>
	<li>Sprinklr, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CXM#NYSE">CXM</a>) shares rose 11.4% to $19.61. Sprinklr shares gained 10% on Wednesday after the company priced its IPO at $16 per share.</li>
	<li>DHI Group, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHX#NYSE">DHX</a>) shares gained 10.6% to $3.0864 after the company announced it will add $12 million to its stock buyback, increasing the overall buyback to $20 million.</li>
	<li>Sierra Wireless, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SWIR#NASDAQ">SWIR</a>) jumped 10.2% to $18.41. Craig-Hallum initiated coverage on Sierra Wireless with a Buy rating and announced a price target of $22.</li>
	<li>Lightning eMotors, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZEV#NYSE">ZEV</a>) surged 10.1% to $8.40. Oppenheimer initiated coverage on Lightning eMotors with an Outperform rating and announced a price target of $15.</li>
	<li>Property Solutions Acquisition Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSAC#NASDAQ">PSAC</a>) rose 8.6% to $16.18 after climbing over 8% on Wednesday.</li>
	<li>Eli Lilly and Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) gained 7.4% to $233.13 after the company said its Donanemab received U.S. FDA&#39;s Breakthrough Therapy designation for the treatment of Alzheimer&#39;s disease.</li>
	<li>Aravive, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARAV#NASDAQ">ARAV</a>) gained 7% to $5.69 after the company announced initial results from the Phase 1b portion of its Phase 1b/2 study of AVB-500. The company said AVB-500 was well tolerated and they plan to expand dosing to 3 additional patients.</li>
	<li>Orphazyme A/S (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ORPH#NASDAQ">ORPH</a>) rose 7% to $7.94. Orphazyme, which recently faced a regulatory setback, said the Goldman Sachs Group briefly increased its stake in Orphazyme above 5%.</li>
	<li>Tower Semiconductor Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSEM#NASDAQ">TSEM</a>) rose 5.5% to $28.85 after the company, and STMicroelectronics, announced an agreement by which ST will welcome Tower to its Agrate R3 300mm fab under construction on its Agrate Brianza site in Italy.</li>
</ul>

 
<a href="https://www.benzinga.com/investing/best-penny-stocks/">Check out these big penny stock gainers and losers</a>

<h3>Losers</h3>

<ul>
	<li>Portage Biotech Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRTG#NASDAQ">PRTG</a>) shares tumbled 25% to $26.11 after the company reported pricing of public offering of 1 million ordinary shares at $23 per share.</li>
	<li>E-Home Household Service Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EJH#NASDAQ">EJH</a>) dipped 13.3% to $28.16.</li>
	<li>Rite Aid Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RAD#NYSE">RAD</a>) fell 12.9% to $17.79 after the company reported weaker-than-expected Q1 sales.</li>
	<li>Aesthetic Medical International Holdings Group Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AIH#NASDAQ">AIH</a>) dropped 12.1% to $7.98 after the company reported Q1 earnings results.</li>
	<li>4D Molecular Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FDMT#NASDAQ">FDMT</a>) dropped 11.8% to $21.84. 4D Molecular Therapeutics an update on their rare disease ophthalmology product candidate portfolio, including initial clinical safety and tolerability data for 4D-110 for choroideremia and 4D-125 for XLRP, and termination of Roche collaboration and license agreement.</li>
	<li>Vinco Ventures, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BBIG#NASDAQ">BBIG</a>) fell 11.1% to $4.2400 after the company announced it will spin out its Emmersive Entertainment unit.</li>
	<li>Adial Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADIL#NASDAQ">ADIL</a>) shares fell 10.8% to $2.6201 after dropping 6% on Wednesday. The company recently announced plans to enter genetic testing market following allowance of U.S. patent for genetic diagnostic test.</li>
	<li>iSpecimen Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISPC#NASDAQ">ISPC</a>) fell 8.7% to $6.02. The company recently priced its IPO at $8 per share.</li>
	<li>DoubleVerify Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DV#NYSE">DV</a>) dropped 6.5% to $40.28.</li>
	<li>ReTo Eco-Solutions, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RETO#NASDAQ">RETO</a>) fell 6.1% to $1.2401. ReTo Eco-Solutions shares gained around 13% on Wednesday after the company announced a $43.7 million project to conduct annual iron ore tailings treatment.</li>
	<li>Talos Energy Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TALO#NYSE">TALO</a>) shares fell 6% to $17.53 after the company reported the pricing of secondary public offering of common stock.</li>
</ul>

36 Stocks Moving In Thursday's Mid-Day Session

&nbsp;

<h3>Gainers</h3>

<ul>
	<li>Pieris Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PIRS#NASDAQ">PIRS</a>) stock moved upwards by 27.11% to $4.5 during Thursday&#39;s regular session. As of 12:30 EST, this security is trading at a volume of 19.5 million shares, making up 208.68% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $262.3 million.</li>
	<li>Kaleido Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KLDO#NASDAQ">KLDO</a>) stock rose 21.6% to $8.5. As of 12:30 EST, this security is trading at a volume of 4.0 million shares, making up 1551.29% of its average full-day volume over the last 100 days. The company&#39;s market cap stands at $361.4 million.</li>
	<li>Arcus Biosciences (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RCUS#NYSE">RCUS</a>) stock moved upwards by 15.33% to $26.99. Arcus Biosciences&#39;s stock is trading at a volume of 2.5 million shares as of 12:30 EST. This is 457.43% of its average full-day volume over the last 100 days. The company&#39;s market cap stands at $1.9 billion.</li>
	<li>NeuroOne Medical Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NMTC#NASDAQ">NMTC</a>) shares rose 13.73% to $6.66. As of 12:30 EST, NeuroOne Medical Tech&#39;s stock is trading at a volume of 11.8K, which is 92.16% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $79.6 million.</li>
	<li>180 Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATNF#NASDAQ">ATNF</a>) stock moved upwards by 13.36% to $11.63. Trading volume for this security as of 12:30 EST is 394.3K, which is 17.07% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $279.9 million.</li>
	<li>Vaxcyte (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCVX#NASDAQ">PCVX</a>) shares increased by 12.38% to $24.14. Vaxcyte&#39;s stock is trading at a volume of 155.7K shares as of 12:30 EST. This is 58.33% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $1.2 billion.</li>
</ul>

&nbsp;

&nbsp;

<h3>Losers</h3>

&nbsp;

<ul>
	<li>Portage Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRTG#NASDAQ">PRTG</a>) stock decreased by 25.65% to $25.88 during Thursday&#39;s regular session. Trading volume for this security as of 12:30 EST is 806.4K, which is 4277.27% of its average full-day volume over the last 100 days.</li>
	<li>Aesthetic Medical Intl (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AIH#NASDAQ">AIH</a>) stock decreased by 12.23% to $7.97. Trading volume for Aesthetic Medical Intl&#39;s stock is 571.6K as of 12:30 EST. This is 148.93% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $188.0 million. The company&#39;s, Q1 earnings came out today.</li>
	<li>4D Molecular Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FDMT#NASDAQ">FDMT</a>) stock declined by 12.15% to $21.77. The current volume of 425.9K shares is 348.06% of 4D Molecular Therapeutics&#39;s average full-day volume over the last 100 days (last updated at 12:30 EST). The company&#39;s market cap stands at $582.2 million.</li>
	<li>Adial Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADIL#NASDAQ">ADIL</a>) shares fell 10.55% to $2.63. As of 12:30 EST, Adial Pharmaceuticals&#39;s stock is trading at a volume of 1.3 million, which is 185.17% of its average full-day volume over the last 100 days. The company&#39;s market cap stands at $47.8 million.</li>
	<li>Corbus Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRBP#NASDAQ">CRBP</a>) shares declined by 9.55% to $1.8. Trading volume for this security as of 12:30 EST is 11.0 million, which is 373.25% of its average full-day volume over the last 100 days. The company&#39;s market cap stands at $225.0 million.</li>
	<li>Idera Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IDRA#NASDAQ">IDRA</a>) stock fell 7.98% to $1.27. As of 12:30 EST, this security is trading at a volume of 3.5 million shares, making up 102.24% of its average full-day volume over the last 100 days. The company&#39;s market cap stands at $63.5 million.</li>
</ul>

&nbsp;

&nbsp;

12 Health Care Stocks Moving In Thursday's Intraday Session

Midway through trading Thursday, the Dow traded up 0.85% to 34,161.06 while the NASDAQ rose 0.80% to 14,386.13. The S&amp;P also rose, gaining 0.61% to 4,267.52.

The U.S. has the highest number of coronavirus cases and deaths in the world, reporting a total of 33,577,710 cases with around 602,830 deaths. India confirmed a total of at least 30,082,770 cases and 391,980 deaths, while Brazil reported over 18,169,880 COVID-19 cases with 507,100 deaths. In total, there were at least 179,635,440 cases of COVID-19 worldwide with more than 3,892,810 deaths, according to data compiled by Johns Hopkins University.

 
Leading and Lagging Sectors

 
Financial shares rose by 0.9% on Thursday. Meanwhile, top gainers in the sector included X Financial (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XYF#NYSE">XYF</a>), up 20%, and LexinFintech Holdings Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LX#NASDAQ">LX</a>), up 8%.

 
In trading on Thursday, real estate shares fell 0.6%.

 
Top Headline

Accenture plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACN#NYSE">ACN</a>) reported stronger-than-expected results for its third quarter and raised its FY21 guidance.

Accenture reported quarterly earnings of $2.40 per share, exceeding analysts&rsquo; estimates of $2.23 per share. The company&rsquo;s quarterly sales came in at $13.30 billion, versus expectations of $12.80 billion.

Accenture said it now expects FY21 EPS of $8.71-$8.80, versus earlier guidance of $8.32-$8.50. The company also boosted its FY21 sales forecast from 6.5%-8.5% to 10%-11%.

&nbsp;

 
Equities Trading UP

 
Digital Brands Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DBGI#NASDAQ">DBGI</a>) shares shot up 54% to $6.28 on heavy volume after the company announced it is expanding its commerce ecosystem by launching a select group of brands on Amazon this Fall.

 
Shares of Marin Software Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRIN#NASDAQ">MRIN</a>) got a boost, shooting 57% to $2.68 after the company announced it has added the ability to manage Instacart Ads to its flagship MarinOne platform.

 
Miromatrix Medical Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MIRO#NASDAQ">MIRO</a>) shares were also up, gaining 43% to $12.91 after the company reported pricing of upsized initial public offering.

<a href="https://www.benzinga.com/movers">Check out these big movers of the day</a>

 
Equities Trading DOWN

Portage Biotech Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRTG#NASDAQ">PRTG</a>) shares tumbled 25% to $25.94 after the company reported pricing of public offering of 1 million ordinary shares at $23 per share.

Shares of Rite Aid Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RAD#NYSE">RAD</a>) were down 14% to $17.60 after the company reported weaker-than-expected Q1 sales.

Vinco Ventures, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BBIG#NASDAQ">BBIG</a>) was down, falling 13% to $4.1289 after the company announced it will spin out its Emmersive Entertainment unit.

Commodities

 
In commodity news, oil traded up 0.1% to $73.12, while gold traded down 0.3% to $1,778.20.

 
Silver traded down 0.1% Thursday to $26.095 while copper fell 0.6% to $4.3040.

 
Euro zone

European shares were higher today. The eurozone&rsquo;s STOXX 600 gained 0.87%, the Spanish Ibex Index climbed 1.34% and the German DAX 30 gained 0.86%. Meanwhile, the London&rsquo;s FTSE 100 rose 0.51%, French CAC 40 climbed 1.22% and Italy&rsquo;s FTSE MIB surged 1.38%.

German Ifo Business Climate indicator increased 2.6% to 101.8 in June, while French manufacturing climate indicator came in unchanged at 107 in June. Spanish gross domestic product contracted 0.4% on quarter during the first three months of the year.

 
Economics

 
US durable goods orders rose 2.3% month-over-month in May.

 
The US economy expanded by an annualized 6.4% in the first quarter.

 
The US goods trade deficit increased to $88.1 billion in May versus a revised $85.7 billion gap in the prior month.

 
US initial jobless claims dropped to 411,000 in the week ending June 19th, versus a revised 418,000 in the prior period.

 
Wholesale inventories rose 1.1% to $707.5 billion in May.

 
US natural-gas supplies climbed 55 billion cubic feet last week, the Energy Information Administration said.

 
The Kansas City Fed&#39;s Manufacturing Production Index fell to 30 in June from 32 in the earlier month..

 
Dallas Fed President Robert Kaplan will speak at 1:00 p.m. ET.

 
St. Louis Fed President James Bullard is set to speak at 1:00 p.m. ET.

 
The Treasury will auction 7-year notes at 1:00 p.m. ET.

<a href="https://www.benzinga.com/calendar/economics/">Check out the full economic calendar here </a>

Mid-Day Market Update: Rite Aid Falls On Downbeat Sales; Marin Software Shares Gain

Portage Biotech shares are trading lower after the company priced its common stock offering of 1 million shares at $23 per share.

Toward the end of trading Thursday, the Dow traded up 1.03% to 34,222.59 while the NASDAQ rose 0.74% to 14,377.16. The S&amp;P also rose, gaining 0.67% to 4,270.15.

The U.S. has the highest number of coronavirus cases and deaths in the world, reporting a total of 33,577,710 cases with around 602,830 deaths. India confirmed a total of at least 30,082,770 cases and 391,980 deaths, while Brazil reported over 18,169,880 COVID-19 cases with 507,100 deaths. In total, there were at least 179,635,440 cases of COVID-19 worldwide with more than 3,892,810 deaths, according to data compiled by Johns Hopkins University.

 
Leading and Lagging Sectors

 
Financial shares rose by 1.3% on Thursday. Meanwhile, top gainers in the sector included X Financial (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XYF#NYSE">XYF</a>), up 20%, and Westwood Holdings Group, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WHG#NYSE">WHG</a>), up 8%.

 
In trading on Thursday, real estate shares fell 0.5%.

 
Top Headline

Accenture plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACN#NYSE">ACN</a>) reported stronger-than-expected results for its third quarter and raised its FY21 guidance.

Accenture reported quarterly earnings of $2.40 per share, exceeding analysts&rsquo; estimates of $2.23 per share. The company&rsquo;s quarterly sales came in at $13.30 billion, versus expectations of $12.80 billion.

Accenture said it now expects FY21 EPS of $8.71-$8.80, versus earlier guidance of $8.32-$8.50. The company also boosted its FY21 sales forecast from 6.5%-8.5% to 10%-11%.

&nbsp;

 
Equities Trading UP

 
Digital Brands Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DBGI#NASDAQ">DBGI</a>) shares shot up 36% to $5.56 on heavy volume after the company announced it is expanding its commerce ecosystem by launching a select group of brands on Amazon this Fall.

 
Shares of Marin Software Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRIN#NASDAQ">MRIN</a>) got a boost, shooting 63% to $2.7799 after the company announced it has added the ability to manage Instacart Ads to its flagship MarinOne platform.

 
Miromatrix Medical Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MIRO#NASDAQ">MIRO</a>) shares were also up, gaining 68% to $15.10 after the company reported pricing of upsized initial public offering.

<a href="https://www.benzinga.com/movers">Check out these big movers of the day</a>

 
Equities Trading DOWN

Portage Biotech Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRTG#NASDAQ">PRTG</a>) shares tumbled 27% to $25.50 after the company reported pricing of public offering of 1 million ordinary shares at $23 per share.

Shares of Rite Aid Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RAD#NYSE">RAD</a>) were down 14% to $17.51 after the company reported weaker-than-expected Q1 sales.

Vinco Ventures, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BBIG#NASDAQ">BBIG</a>) was down, falling 12% to $4.2299 after the company announced it will spin out its Emmersive Entertainment unit.

Commodities

 
In commodity news, oil traded up 0.3% to $73.33, while gold traded down 0.3% to $1,777.70.

 
Silver traded down 0.1% Thursday to $26.075 while copper fell 0.1% to $4.3250.

 
Euro zone

European shares closed higher today. The eurozone&rsquo;s STOXX 600 gained 0.87%, the Spanish Ibex Index climbed 1.34% and the German DAX 30 gained 0.86%. Meanwhile, the London&rsquo;s FTSE 100 rose 0.51%, French CAC 40 climbed 1.22% and Italy&rsquo;s FTSE MIB surged 1.38%.

German Ifo Business Climate indicator increased 2.6% to 101.8 in June, while French manufacturing climate indicator came in unchanged at 107 in June. Spanish gross domestic product contracted 0.4% on quarter during the first three months of the year.

 
Economics

 
US durable goods orders rose 2.3% month-over-month in May.

 
The US economy expanded by an annualized 6.4% in the first quarter.

 
The US goods trade deficit increased to $88.1 billion in May versus a revised $85.7 billion gap in the prior month.

 
US initial jobless claims dropped to 411,000 in the week ending June 19th, versus a revised 418,000 in the prior period.

 
Wholesale inventories rose 1.1% to $707.5 billion in May.

 
US natural-gas supplies climbed 55 billion cubic feet last week, the Energy Information Administration said.

 
The Kansas City Fed&#39;s Manufacturing Production Index fell to 30 in June from 32 in the earlier month..

 
<a href="https://www.benzinga.com/calendar/economics/">Check out the full economic calendar here </a>

Mid-Afternoon Market Update: Dow Jumps Over 300 Points; Portage Biotech Shares Slide

<h3>Gainers</h3>

<ul>
	<li>Marin Software Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRIN#NASDAQ">MRIN</a>) shares surged 105.3% to close at $3.51 on Thursday after the company announced it has added the ability to manage Instacart Ads to its flagship MarinOne platform.</li>
	<li>Miromatrix Medical Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MIRO#NASDAQ">MIRO</a>) shares climbed 69.3% to settle at $15.24 after the company reported pricing of upsized initial public offering.</li>
	<li>Digital Brands Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DBGI#NASDAQ">DBGI</a>) shares gained 31.1% to close at $5.36 after the company reported channel expansion into Amazon Marketplace.</li>
	<li>Confluent, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CFLT#NASDAQ">CFLT</a>) gained 25.1% to close at $45.02 after the company priced its IPO at $36 per share.</li>
	<li>FreightCar America, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RAIL#NASDAQ">RAIL</a>) gained 24.6% to settle at $7.20 amid President Joe Biden declaring that the White House had struck an infrastructure deal with a bipartisan group of senators.</li>
	<li>Pieris Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PIRS#NASDAQ">PIRS</a>) climbed 23.5% to close at $4.37 after the company announced it received Orphan Drug Designation for cinrebafusp alfa for the treatment of gastric cancer.</li>
	<li>Celcuity Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CELC#NASDAQ">CELC</a>) gained 20.8% to settle at $30.49 on below-average volume.</li>
	<li>GTT Communications, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GTT#NYSE">GTT</a>) jumped 20.2% to close at $2.98 after surging over 13% on Wednesday.</li>
	<li>Synchronoss Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNCR#NASDAQ">SNCR</a>) climbed 19.8% to close at $2.91.</li>
	<li>X Financial (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XYF#NYSE">XYF</a>) climbed 19.7% to close at $11.56.</li>
	<li>DHI Group, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHX#NYSE">DHX</a>) shares jumped 19.7% to close at $3.34 after the company announced it will add $12 million to its stock buyback, increasing the overall buyback to $20 million.</li>
	<li>Altisource Portfolio Solutions S.A. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASPS#NASDAQ">ASPS</a>) gained 19.7% to settle at $7.77.</li>
	<li>Gold Royalty Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GROY#NYSE">GROY</a>) rose 17.8% to close at $6.66.</li>
	<li>Condor Hospitality Trust, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CDOR#NYSE">CDOR</a>) gained 17.6% to close at $6.27.</li>
	<li>Processa Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCSA#NASDAQ">PCSA</a>) rose 16.1% to settle at $8.74. Processa Pharmaceuticals recently entered into a licensing agreement with Ocuphire Pharma to in-license RX-3117.</li>
	<li>The Trade Desk, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTD#NASDAQ">TTD</a>) jumped 16% to settle at $75.88 mid strength in advertising technology stocks after Google announced it is delaying the phase-out of third-party cookies on Chrome until 2023.</li>
	<li>Regional Health Properties, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RHE#NYSE">RHE</a>) gained 15.6% to close at $14.48.</li>
	<li>Live Ventures Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LIVE#NASDAQ">LIVE</a>) jumped 15.6% to settle at $69.78.</li>
	<li>SEMrush Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SEMR#NYSE">SEMR</a>) surged 15.5% to close at $23.34.</li>
	<li>Arcus Biosciences, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RCUS#NYSE">RCUS</a>) shares surged 15.5% to close at $27.02 after the company disclosed data from the first interim analysis of the three-arm randomized Phase 2 ARC-7 study.</li>
	<li>Moxian, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MOXC#NASDAQ">MOXC</a>) rose 14.7% to close at $23.04 after jumping 22% on Wednesday.</li>
	<li>Kaleido Biosciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KLDO#NASDAQ">KLDO</a>) climbed 13.5% to close at $7.93 on above-average volume.</li>
	<li>Grove, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRVI#NASDAQ">GRVI</a>) rose 12% to settle at $5.60 after the company priced its IPO at $5 per share.</li>
	<li>Sprinklr, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CXM#NYSE">CXM</a>) shares gained 11.6% to close at $19.64. Sprinklr shares gained 10% on Wednesday after the company priced its IPO at $16 per share.</li>
	<li>Sierra Wireless, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SWIR#NASDAQ">SWIR</a>) gained 11.6% to settle at $18.63. Craig-Hallum initiated coverage on Sierra Wireless with a Buy rating and announced a price target of $22.</li>
	<li>India Globalization Capital, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IGC#NYSE">IGC</a>) gained 11.5% to close at $1.65. IGC said it has completed the final Cohort of its Phase 1 Clinical trial on Alzheimer&rsquo;s patients.</li>
	<li>Uxin Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UXIN#NASDAQ">UXIN</a>) gained 9.9% to settle at $4.11 after gaining over 7% on Wednesday.</li>
	<li>Orphazyme A/S (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ORPH#NASDAQ">ORPH</a>) rose 9.5% to close at $8.15. Orphazyme, which recently faced a regulatory setback, said the Goldman Sachs Group briefly increased its stake in Orphazyme above 5%.</li>
	<li>Lightning eMotors, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZEV#NYSE">ZEV</a>) gained 9.2% to close at $8.33. Oppenheimer initiated coverage on Lightning eMotors with an Outperform rating and announced a price target of $15.</li>
	<li>Compugen Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGEN#NASDAQ">CGEN</a>) rose 8.9% to close at $8.47. The company recently announced updated data from its Phase 1 dose-escalation and expansion study of COM701 as a monotherapy and in a dose-escalation combination study with Bristol-Myers Squibb&rsquo;s Opdivo (nivolumab).</li>
	<li>Eli Lilly and Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) climbed 7.3% to close at $232.97 after the company said its Donanemab received U.S. FDA&#39;s Breakthrough Therapy designation for the treatment of Alzheimer&#39;s disease.</li>
	<li>Tower Semiconductor Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSEM#NASDAQ">TSEM</a>) gained 6.2% to close at $29.05 after the company, and STMicroelectronics, announced an agreement by which ST will welcome Tower to its Agrate R3 300mm fab under construction on its Agrate Brianza site in Italy.</li>
	<li>Aravive, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARAV#NASDAQ">ARAV</a>) rose 5.3% to close at $5.60 after the company announced initial results from the Phase 1b portion of its Phase 1b/2 study of AVB-500. The company said AVB-500 was well tolerated and they plan to expand dosing to 3 additional patients.</li>
</ul>

 
<a href="https://www.benzinga.com/investing/best-penny-stocks/">Check out these big penny stock gainers and losers</a>

<h3>Losers</h3>

<ul>
	<li>Portage Biotech Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRTG#NASDAQ">PRTG</a>) shares dipped 25.4% to close at $25.95 on Thursday after the company reported pricing of public offering of 1 million ordinary shares at $23 per share.</li>
	<li>Rite Aid Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RAD#NYSE">RAD</a>) fell 14.5% to close at $17.46 after the company reported weaker-than-expected Q1 sales.</li>
	<li>Adial Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADIL#NASDAQ">ADIL</a>) shares declined 14.3% to close at $2.52 after dropping 6% on Wednesday. The company recently announced plans to enter genetic testing market following allowance of U.S. patent for genetic diagnostic test.</li>
	<li>Aesthetic Medical International Holdings Group Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AIH#NASDAQ">AIH</a>) dipped 12.9% to settle at $7.91 after the company reported Q1 earnings results.</li>
	<li>Talaris Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TALS#NASDAQ">TALS</a>) fell 10.9% to settle at $13.69. The company recently reported a wider quarterly loss.</li>
	<li>Vinco Ventures, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BBIG#NASDAQ">BBIG</a>) fell 10.7% to close at $4.26 after the company announced it will spin out its Emmersive Entertainment unit.</li>
	<li>4D Molecular Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FDMT#NASDAQ">FDMT</a>) fell 10.4% to close at $22.20. 4D Molecular Therapeutics an update on their rare disease ophthalmology product candidate portfolio, including initial clinical safety and tolerability data for 4D-110 for choroideremia and 4D-125 for XLRP, and termination of Roche collaboration and license agreement.</li>
	<li>Clearside Biomedical, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLSD#NASDAQ">CLSD</a>) tumbled 10% to settle at $4.84.</li>
	<li>DouYu International Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DOYU#NASDAQ">DOYU</a>) dropped 9.8% to close at $7.11.</li>
	<li>Oasis Midstream Partners LP (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OMP#NASDAQ">OMP</a>) fell 9.3% to close at $27.93. Oasis Midstream Partners priced its public offering of 3.623 million common units after the closing bell on Thursday.</li>
	<li>Terns Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TERN#NASDAQ">TERN</a>) dipped 9.2% to settle at $13.39. Terns reported initiation of patient dosing in AVIATION Phase 1b NASH clinical trial of VAP-1 Inhibitor TERN-201 after the closing bell.</li>
	<li>Talos Energy Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TALO#NYSE">TALO</a>) shares fell 6.4% to close at $17.45 after the company reported the pricing of secondary public offering of common stock.</li>
</ul>

45 Biggest Movers From Yesterday

<h3>Gainers</h3>

<ul>
	<li>Verb Technology Company, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERB#NASDAQ">VERB</a>) rose 44.5% to $2.24 in pre-market trading. Verb Technology shares gained over 17% on Tuesday after Ascendiant Capital initiated coverage on the stock with a Buy rating and a $4 price target.</li>
	<li>Bridgeline Digital, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLIN#NASDAQ">BLIN</a>) shares rose 43.7% to $4.87 in pre-market trading. Bridgeline Digital shares jumped over 36% on Tuesday on above-average volume.</li>
	<li>Vertex Energy, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VTNR#NASDAQ">VTNR</a>) shares rose 43.4% to $14.73 in pre-market trading after the company agreed To divest used motor oil collection and recycling assets for $140 million to Clean Harbors.</li>
	<li>Borqs Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRQS#NASDAQ">BRQS</a>) rose 34.7% to $1.34 in pre-market trading after gaining 11% on Tuesday. Borqs Technologies recently said it started delivery of cellular CTA-2045 products to SkyCentrics for use by utility companies for smart city deployment.</li>
	<li>Powerbridge Technologies Co., Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PBTS#NASDAQ">PBTS</a>) rose 19.6% to $3.42 in pre-market trading after jumping 100% on Tuesday.</li>
	<li>Exela Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XELA#NASDAQ">XELA</a>) rose 16.2% to $2.72 in pre-market trading. Exela Technologies shares jumped over 59% on Tuesday possibly on increased retail investor interest in the stock. Exela Technologies also announced the rollout of EON, its Robotic Process Automation platform for a large health insurance company.</li>
	<li>LMP Automotive Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LMPX#NASDAQ">LMPX</a>) rose 16% to $20.50 in pre-market trading after the company swung to a profit in the first quarter.</li>
	<li>HUTCHMED (China) Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HCM#NASDAQ">HCM</a>) rose 15.8% to $38.48 in pre-market trading. HUTCHMED and AstraZeneca&#39;s Orpathys recently received conditional approval in China.</li>
	<li>Inpixon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INPX#NASDAQ">INPX</a>) rose 8.8% to $1.24 in pre-market trading. Inpixon was added to Russell Microcap Index, effective June 28.</li>
	<li>MingZhu Logistics Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/YGMZ#NASDAQ">YGMZ</a>) rose 8.8% to $4.80 in pre-market trading after the company announced it regained NASDAQ compliance.</li>
	<li>AMMO, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/POWW#NASDAQ">POWW</a>) rose 7.7% to $9.47 in pre-market trading after the company reported better-than-expected Q4 results.</li>
	<li>Xcel Brands, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XELB#NASDAQ">XELB</a>) shares rose 6.3% to $2.55 in pre-market trading after gaining over 5% on Tuesday.</li>
</ul>

 
 
Find out what&#39;s going on in today&#39;s market and bring any questions you have to <a href="http://premarket.benzinga.com/pre-market-show/">Benzinga&#39;s PreMarket Prep</a>.

<a href="https://www.benzinga.com/investing/best-penny-stocks/">Check out these big penny stock gainers and losers</a>

<h3>Losers</h3>

<ul>
	<li>Altimmune, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALT#NASDAQ">ALT</a>) fell 34.4% to $10.45 in pre-market trading after the company announced it will discontinue further development of AdCOVID and focus resources on obesity and liver programs.</li>
	<li>Kiromic BioPharma, Inc.. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KRBP#NASDAQ">KRBP</a>) fell 25.2% to $4.97 in pre-market trading after dropping 17% on Tuesday. The company recently announced it will be presenting at the 2021 Next-Gen Immuno Oncology Congress.</li>
	<li>Panbela Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PBLA#NASDAQ">PBLA</a>) shares fell 25.1% to $2.86 in pre-market trading after the company reported a $5 million bought deal offering of common stock.</li>
	<li>Marin Software Incorporated (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mrin#NASDAQ" style="font-size: 13px;">MRIN</a>) fell 20.4% to $13.79 in pre-market trading after jumping over 130% on Tuesday. Marin Software, last week, announced it has added the ability to manage Instacart Ads to its flagship MarinOne platform.</li>
	<li>BSQUARE Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BSQR#NASDAQ">BSQR</a>) fell 17.3% to $6.65 in pre-market trading after jumping over 206% on Tuesday.</li>
	<li>electroCore, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ECOR#NASDAQ">ECOR</a>) fell 16.1% to $1.25 in pre-market trading after the company reported a common stock offering.</li>
	<li>Qumu Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QUMU#NASDAQ">QUMU</a>) shares fell 16.1% to $3.23 in pre-market trading after the company reported weak preliminary revenue for the second quarter.</li>
	<li>Auddia Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AUUD#NASDAQ">AUUD</a>) shares fell 11.1% to $6.23 in pre-market trading. Auddia shares gained 19% on Tuesday after the company announced the release and national launch of its flagship Auddia app ahead of schedule.</li>
	<li>Cerevel Therapeutics Holdings, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cere#NASDAQ" style="font-size: 13px;">CERE</a>) fell 9.2% to $26.96 in pre-market trading. Cerevel Therapeutics shares jumped 136% on Tuesday after the company announced topline results from Phase 1b trial of CVL-231, saying both doses of CVL-231 demonstrated a clinically meaningful and statistically significant improvement in PANSS Total score.</li>
	<li>MongoDB, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDB#NASDAQ">MDB</a>) shares fell 6.5% to $358.60 in pre-market trading after the company priced an underwritten public offering of 2,500,000 shares of its Class A common stock at $365.00 per share.</li>
	<li>Eagle Bulk Shipping Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EGLE#NASDAQ">EGLE</a>) shares fell 6.2% to $48.00 in pre-market trading after the company reported the pricing of an underwritten secondary public offering of 1,695,182 shares of common stock at $46.50 per share.</li>
</ul>

23 Stocks Moving in Wednesday's Pre-Market Session

&nbsp;

During Wednesday&#39;s morning session, 29 stocks hit new 52-week lows.

<h2>Points of Interest:</h2>

<ul>
	<li>The largest company by market cap to set a new 52-week low was CoStar Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSGP#NASDAQ">CSGP</a>).</li>
	<li>The smallest company in terms of market cap to set a new 52-week low was Panbela Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PBLA#NASDAQ">PBLA</a>).</li>
	<li>Kiromic BioPharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KRBP#NASDAQ">KRBP</a>)&#39;s stock made the biggest move downwards, diving 27.94% to reach a new 52-week low.</li>
</ul>

The following stocks created new 52-week lows as of 10 a.m. ET on Wednesday:

<ul>
	<li>CoStar Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSGP#NASDAQ">CSGP</a>) stock broke to a new 52-week low of $82.60 on Wednesday. Shares of the company traded down 0.22%.</li>
	<li>Cano Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CANO#NYSE">CANO</a>) shares hit a yearly low of $11.33. The stock was down 2.44% on the session.</li>
	<li>Frontier Group Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ULCC#NASDAQ">ULCC</a>) shares fell to $16.38 on Wednesday, setting a new 52-week low with a shift of up 1.76%.</li>
	<li>Novagold Resources (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/NG#AMEX">NG</a>) stock hit a yearly low of $7.86. The stock was down 1.13% for the day.</li>
	<li>Buenaventura Mining Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BVN#NYSE">BVN</a>) shares moved 0.0% (flat) on Wednesday to hit a new 52-week low of $8.68, drifting 0.0% (flat).</li>
	<li>Global Blood Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GBT#NASDAQ">GBT</a>) stock achieved a new 52-week low on Wednesday morning, hitting $31.90 and moving up 3.7%.</li>
	<li>Equinox Gold (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/EQX#AMEX">EQX</a>) stock hit a new 52-week low of $6.83. The stock was up 0.8% on the session.</li>
	<li>Madrigal Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDGL#NASDAQ">MDGL</a>) shares were up 0.9% for the day, having made a 52-week low of $95.21.</li>
	<li>GreenTree Hospitality Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GHG#NYSE">GHG</a>) stock drifted up 0.36% on Wednesday morning to hit a new 52-week low of $10.77.</li>
	<li>Mersana Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRSN#NASDAQ">MRSN</a>) stock drifted up 3.54% on Wednesday morning to hit a new 52-week low of $13.10.</li>
	<li>17 Education &amp; Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/YQ#NASDAQ">YQ</a>) shares fell to $3.40 on Wednesday, setting a new 52-week low with a shift of up 3.17%.</li>
	<li>NRX Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NRXP#NASDAQ">NRXP</a>) shares fell to $11.73 on Wednesday, setting a new 52-week low with a shift of down 0.54%.</li>
	<li>VectivBio Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VECT#NASDAQ">VECT</a>) shares made a new 52-week low of $11.04 on Wednesday. The stock was down 4.5% for the day.</li>
	<li>Neoleukin Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NLTX#NASDAQ">NLTX</a>) shares moved down 1.71% on Wednesday to hit a new 52-week low of $9.20, drifting down 1.71%.</li>
	<li>Athersys (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATHX#NASDAQ">ATHX</a>) shares set a new yearly low of $1.37 this morning. The stock was down 0.35% on the session.</li>
	<li>Burcon NutraScience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRCN#NASDAQ">BRCN</a>) shares moved down 1.38% on Wednesday to hit a new 52-week low of $2.81, drifting down 1.38%.</li>
	<li>Terns Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TERN#NASDAQ">TERN</a>) stock achieved a new 52-week low on Wednesday morning, hitting $12.15 and moving down 2.17%.</li>
	<li>Portage Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRTG#NASDAQ">PRTG</a>) stock drifted down 0.35% on Wednesday morning to hit a new 52-week low of $22.22.</li>
	<li>Innate Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IPHA#NASDAQ">IPHA</a>) stock drifted down 6.98% on Wednesday morning to hit a new 52-week low of $3.25.</li>
	<li>China Online Education Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COE#NYSE">COE</a>) stock hit a yearly low of $7.80. The stock was down 2.37% for the day.</li>
	<li>Medicenna Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDNA#NASDAQ">MDNA</a>) stock broke to a new 52-week low of $2.85 on Wednesday. Shares of the company traded down 0.84%.</li>
	<li>Caledonia Mining Corp (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/CMCL#AMEX">CMCL</a>) shares moved up 0.49% on Wednesday to hit a new 52-week low of $12.10, drifting up 0.49%.</li>
	<li>IMV (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMV#NASDAQ">IMV</a>) stock hit $2.05 on Wednesday morning, setting a new 52-week low for a change of down 3.25%.</li>
	<li>ImmunoPrecise Antibodies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IPA#NASDAQ">IPA</a>) shares fell to $6.13 on Wednesday, setting a new 52-week low with a shift of down 0.96%.</li>
	<li>Vivos Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VVOS#NASDAQ">VVOS</a>) shares were down 0.31% for the day, having made a 52-week low of $4.80.</li>
	<li>5:01 Acquisition (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FVAM#NASDAQ">FVAM</a>) shares fell to $9.61 on Wednesday, setting a new 52-week low with a shift of down 1.45%.</li>
	<li>Inhibikase Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IKT#NASDAQ">IKT</a>) stock achieved a new 52-week low on Wednesday morning, hitting $2.75 and moving down 2.46%.</li>
	<li>Kiromic BioPharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KRBP#NASDAQ">KRBP</a>) shares were down 27.94% for the day, having made a 52-week low of $4.75.</li>
	<li>Panbela Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PBLA#NASDAQ">PBLA</a>) stock achieved a new 52-week low on Wednesday morning, hitting $2.82 and moving down 25.92%.</li>
</ul>

&nbsp;

Benzinga will continue to provide updates on these equities. Stay tuned for additional news.

Stocks That Hit 52-Week Lows On Wednesday

&nbsp;

<h1>&nbsp;</h1>

Thursday&#39;s morning session saw 13 companies set new 52-week lows.

<h2>Things to Consider:</h2>

<ul>
	<li>Edgewise Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EWTX#NASDAQ">EWTX</a>) was the largest firm by market cap to set a new 52-week low.</li>
	<li>Save Foods (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SVFD#NASDAQ">SVFD</a>) was the smallest firm by market cap to set a new 52-week low.</li>
	<li>Portage Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRTG#NASDAQ">PRTG</a>)&#39;s stock dropped the most, trading down 2.58% to reach a new 52-week low.</li>
</ul>

Here are all the stocks that set new 52-week lows as of 10 a.m. ET on Thursday:

<ul>
	<li>Edgewise Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EWTX#NASDAQ">EWTX</a>) stock dropped to a yearly low on Thursday of $20.96. Shares traded down 0.23%.</li>
	<li>Theravance Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TBPH#NASDAQ">TBPH</a>) stock hit a yearly low of $14.31. The stock was up 0.21% for the day.</li>
	<li>CareMax (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMAX#NASDAQ">CMAX</a>) stock set a new 52-week low of $12.16 on Thursday, moving down 2.05%.</li>
	<li>SOC Telemed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLMD#NASDAQ">TLMD</a>) shares set a new yearly low of $5.56 this morning. The stock was down 1.23% on the session.</li>
	<li>Falcon Capital (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FCAC#NASDAQ">FCAC</a>) shares set a new 52-week low of $9.18. The stock traded up 0.11%.</li>
	<li>ION Acquisition Corp 3 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IACC#NYSE">IACC</a>) shares moved 0.0% (flat) on Thursday to hit a new 52-week low of $9.76, drifting 0.0% (flat).</li>
	<li>Freeline Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FRLN#NASDAQ">FRLN</a>) shares set a new yearly low of $8.13 this morning. The stock was up 1.72% on the session.</li>
	<li>Portage Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRTG#NASDAQ">PRTG</a>) stock hit a yearly low of $20.72. The stock was up 2.58% for the day.</li>
	<li>Altimar Acquisition Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ATAQ#NYSE">ATAQ</a>) stock achieved a new 52-week low on Thursday morning, hitting $9.71 and moving down 0.41%.</li>
	<li>Hycroft Mining Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HYMC#NASDAQ">HYMC</a>) shares hit a yearly low of $2.81. The stock was down 1.96% on the session.</li>
	<li>RISE Education Cayman (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REDU#NASDAQ">REDU</a>) stock hit a new 52-week low of $2.53. The stock was down 0.38% on the session.</li>
	<li>Biophytis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BPTS#NASDAQ">BPTS</a>) stock drifted down 0.66% on Thursday morning to hit a new 52-week low of $9.50.</li>
	<li>Save Foods (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SVFD#NASDAQ">SVFD</a>) stock hit a yearly low of $7.51. The stock was up 0.75% for the day.</li>
</ul>

&nbsp;

Benzinga will update traders on these companies going forward. If these companies break to a new level, Benzinga will be the first to report on it.

Stocks That Hit 52-Week Lows On Thursday

Biohaven Reports Q2 NURTEC ODT Sales of $93M

&nbsp;

Before 10 a.m. ET on Wednesday, 49 companies set new 52-week lows.

<h2>Noteworthy Highlights:</h2>

<ul>
	<li>The largest company in terms of market cap to set a new 52-week low was China Life Insurance Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LFC#NYSE">LFC</a>).</li>
	<li>Chembio Diagnostics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CEMI#NASDAQ">CEMI</a>) was the smallest firm on a market cap basis to set a new 52-week low.</li>
	<li>UTime (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UTME#NASDAQ">UTME</a>) saw the most pronounced move, as shares traded down 3.31% to hit its new 52-week low.</li>
</ul>

The following stocks set new 52-week lows as of 10 a.m. ET on Wednesday:

<ul>
	<li>China Life Insurance Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LFC#NYSE">LFC</a>) stock drifted down 0.75% on Wednesday morning to hit a new 52-week low of $9.25.</li>
	<li>Confluent (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CFLT#NASDAQ">CFLT</a>) stock hit $42.02 on Wednesday morning, setting a new 52-week low for a change of down 0.26%.</li>
	<li>Playtika Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLTK#NASDAQ">PLTK</a>) stock hit $22.28 on Wednesday morning, setting a new 52-week low for a change of down 0.92%.</li>
	<li>AbCellera Biologics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABCL#NASDAQ">ABCL</a>) stock set a new 52-week low of $18.92 on Wednesday, moving down 1.89%.</li>
	<li>Galapagos (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLPG#NASDAQ">GLPG</a>) shares fell to $67.02 on Wednesday, setting a new 52-week low with a shift of down 1.52%.</li>
	<li>Xometry (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XMTR#NASDAQ">XMTR</a>) stock achieved a new 52-week low on Wednesday morning, hitting $62.89 and moving down 3.04%.</li>
	<li>Cal-Maine Foods (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CALM#NASDAQ">CALM</a>) stock dropped to a yearly low on Wednesday of $34.42. Shares traded down 0.72%.</li>
	<li>Air Transport Services Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATSG#NASDAQ">ATSG</a>) stock achieved a new 52-week low on Wednesday morning, hitting $21.99 and moving down 1.21%.</li>
	<li>SiriusPoint (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPNT#NYSE">SPNT</a>) stock dropped to a yearly low on Wednesday of $9.80. Shares traded down 0.3%.</li>
	<li>Original BARK (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BARK#NYSE">BARK</a>) stock hit a yearly low of $9.21. The stock was down 2.7% for the day.</li>
	<li>Smart Share Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EM#NASDAQ">EM</a>) shares set a new yearly low of $5.54 this morning. The stock was down 0.89% on the session.</li>
	<li>Cloopen Group Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RAAS#NYSE">RAAS</a>) stock set a new 52-week low of $6.93 on Wednesday, moving down 0.83%.</li>
	<li>AlloVir (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALVR#NASDAQ">ALVR</a>) stock hit $18.67 on Wednesday morning, setting a new 52-week low for a change of up 0.37%.</li>
	<li>Mersana Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRSN#NASDAQ">MRSN</a>) shares set a new yearly low of $12.79 this morning. The stock was down 0.31% on the session.</li>
	<li>Vintage Wine Estates (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VWE#NASDAQ">VWE</a>) stock set a new 52-week low of $11.06 on Wednesday, moving up 0.9%.</li>
	<li>Alzamend Neuro (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALZN#NASDAQ">ALZN</a>) shares reached a new 52-week low of $6.60 on Wednesday morning, moving down 2.01%.</li>
	<li>Pharvaris (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PHVS#NASDAQ">PHVS</a>) shares hit a yearly low of $15.08. The stock was up 2.26% on the session.</li>
	<li>Bolt Biotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BOLT#NASDAQ">BOLT</a>) shares set a new 52-week low of $14.02. The stock traded down 0.35%.</li>
	<li>Black Diamond Therapeutic (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BDTX#NASDAQ">BDTX</a>) shares reached a new 52-week low of $11.18 on Wednesday morning, moving down 1.81%.</li>
	<li>CytomX Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTMX#NASDAQ">CTMX</a>) stock drifted down 0.66% on Wednesday morning to hit a new 52-week low of $6.01.</li>
	<li>Plum Acquisition (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLMI#NASDAQ">PLMI</a>) shares set a new 52-week low of $9.65. The stock traded up 0.52%.</li>
	<li>Neoleukin Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NLTX#NASDAQ">NLTX</a>) shares hit a yearly low of $9.05. The stock was down 0.43% on the session.</li>
	<li>Finserv Acquisition Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FSRX#NASDAQ">FSRX</a>) shares were 0.0% (flat) for the day, having made a 52-week low of $9.65.</li>
	<li>89bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ETNB#NASDAQ">ETNB</a>) stock achieved a new 52-week low on Wednesday morning, hitting $16.56 and moving up 0.18%.</li>
	<li>Angion Biomedica (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANGN#NASDAQ">ANGN</a>) shares moved up 0.75% on Wednesday to hit a new 52-week low of $11.02, drifting up 0.75%.</li>
	<li>Biodesix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BDSX#NASDAQ">BDSX</a>) shares set a new yearly low of $11.27 this morning. The stock was down 0.51% on the session.</li>
	<li>Kala Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KALA#NASDAQ">KALA</a>) stock hit a yearly low of $4.62. The stock was down 2.37% for the day.</li>
	<li>Social Capital Suvretta (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DNAA#NASDAQ">DNAA</a>) shares reached a new 52-week low of $10.00 on Wednesday morning, moving down 0.2%.</li>
	<li>Cogent Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COGT#NASDAQ">COGT</a>) stock hit a new 52-week low of $7.05. The stock was down 2.96% on the session.</li>
	<li>Terns Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TERN#NASDAQ">TERN</a>) stock drifted up 1.1% on Wednesday morning to hit a new 52-week low of $10.50.</li>
	<li>Portage Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRTG#NASDAQ">PRTG</a>) stock achieved a new 52-week low on Wednesday morning, hitting $20.25 and moving down 1.69%.</li>
	<li>Gemini Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GMTX#NASDAQ">GMTX</a>) shares hit a yearly low of $5.63. The stock was down 0.35% on the session.</li>
	<li>Lead Edge Growth Opps (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LEGA#NASDAQ">LEGA</a>) shares made a new 52-week low of $9.65 on Wednesday. The stock was down 0.31% for the day.</li>
	<li>Waitr Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WTRH#NASDAQ">WTRH</a>) shares moved up 0.09% on Wednesday to hit a new 52-week low of $1.73, drifting up 0.09%.</li>
	<li>Miromatrix Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MIRO#NASDAQ">MIRO</a>) stock drifted down 3.01% on Wednesday morning to hit a new 52-week low of $9.72.</li>
	<li>Surgalign Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRGA#NASDAQ">SRGA</a>) shares reached a new 52-week low of $1.27 on Wednesday morning, moving down 0.76%.</li>
	<li>Voyager Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VYGR#NASDAQ">VYGR</a>) shares set a new yearly low of $3.76 this morning. The stock was down 1.31% on the session.</li>
	<li>NeuBase Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NBSE#NASDAQ">NBSE</a>) stock set a new 52-week low of $4.16 on Wednesday, moving down 1.17%.</li>
	<li>Puxin (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NEW#NYSE">NEW</a>) shares set a new 52-week low of $1.53. The stock traded down 2.48%.</li>
	<li>Jiuzi Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JZXN#NASDAQ">JZXN</a>) stock dropped to a yearly low on Wednesday of $6.25. Shares traded down 2.57%.</li>
	<li>Biophytis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BPTS#NASDAQ">BPTS</a>) stock achieved a new 52-week low on Wednesday morning, hitting $9.00 and moving down 0.44%.</li>
	<li>Meten EdtechX Education (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/METX#NASDAQ">METX</a>) stock hit a yearly low of $0.83. The stock was down 0.53% for the day.</li>
	<li>UTime (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UTME#NASDAQ">UTME</a>) stock drifted down 3.31% on Wednesday morning to hit a new 52-week low of $9.60.</li>
	<li>Protalix BioTherapeutics (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/PLX#AMEX">PLX</a>) stock set a new 52-week low of $1.72 on Wednesday, moving down 2.79%.</li>
	<li>Rockwell Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RMTI#NASDAQ">RMTI</a>) stock broke to a new 52-week low of $0.82 on Wednesday. Shares of the company traded down 0.81%.</li>
	<li>Celyad Oncology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYAD#NASDAQ">CYAD</a>) shares set a new 52-week low of $5.05. The stock traded down 0.01%.</li>
	<li>Tian Ruixiang Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TIRX#NASDAQ">TIRX</a>) stock hit a yearly low of $5.37. The stock was down 1.92% for the day.</li>
	<li>FedNat Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FNHC#NASDAQ">FNHC</a>) shares were 0.0% (flat) for the day, having made a 52-week low of $3.70.</li>
	<li>Chembio Diagnostics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CEMI#NASDAQ">CEMI</a>) shares fell to $2.77 on Wednesday, setting a new 52-week low with a shift of down 0.36%.</li>
</ul>

&nbsp;

Be sure to monitor Benzinga for the news traders need!

<h3>Gainers</h3>

<ul>
	<li>Newegg Commerce, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEGG#NASDAQ">NEGG</a>) jumped 79% to $48.70 after jumping around 42% on Tuesday.</li>
	<li>OncoSec Medical Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONCS#NASDAQ">ONCS</a>) shares climbed 46.7% to $4.0936 after the company said it will evaluate its DNA-plasmid interleukin-12 (IL-12) TAVO (tavokinogene telseplasmid) with Merck &amp; Co&rsquo;s Keytruda (pembrolizumab) in KEYNOTE-C87 Phase 3 trial..</li>
	<li>Data Storage Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DTST#NASDAQ">DTST</a>) shares jumped 46.4% to $10.67. Data Storage shares jumped over 24% on Tuesday on above-average volume.</li>
	<li>Bon Natural Life Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BON#NASDAQ">BON</a>) gained 44.8% to $14.74. Bon Natural Life recently received the certificate of a land use right for the future site of its third production facility in the city of Yumen.</li>
	<li>Virpax Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRPX#NASDAQ">VRPX</a>) rose 32% to $6.01 after the company issued a progress update on product candidates.</li>
	<li>Dar&eacute; Bioscience, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DARE#NASDAQ">DARE</a>) climbed 31.6% to $1.9998 on a report suggesting the company entered into an agreement with the Bill &amp; Melinda Gates Foundation and were awarded a new grant of up to $48.95 million to support development of DARE-LARC1.</li>
	<li>Opiant Pharmaceuticals Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPNT#NASDAQ">OPNT</a>) shares gained 21.4% to $16.09 after the company disclosed top-line results from its confirmatory pharmacokinetic study for OPNT003, nasal nalmefene, for opioid overdose.</li>
	<li>X Financial (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XYF#NYSE">XYF</a>) gained 16.6% to $13.55.</li>
	<li>SMART Global Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGH#NASDAQ">SGH</a>) surged 13.7% to $54.06 after the company reported better-than-expected Q3 results. The company also issued Q4 guidance above analyst estimates.</li>
	<li>iSpecimen Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISPC#NASDAQ">ISPC</a>) jumped 11.8% to $6.93. The company, last month, priced its IPO at $8 per share.</li>
	<li>INmune Bio, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INMB#NASDAQ">INMB</a>) gained 10.4% to $19.71.</li>
	<li>Biohaven Pharmaceutical Holding Company Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BHVN#NYSE">BHVN</a>) surged 9.9% to $108.70. Biohaven reported Q2 NURTEC ODT sales of $93 million.</li>
	<li>Performant Financial Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PFMT#NASDAQ">PFMT</a>) jumped 9.7% to $3.73. Craig-Hallum initiated coverage on Performant Financial with a Buy rating and announced a price target of $10.</li>
	<li>JinkoSolar Holding Co., Ltd(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JKS#NYSE">JKS</a>) shares rose 8.7% to $59.07 after gaining around 8% on Tuesday.</li>
	<li>Vivos Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VVOS#NASDAQ">VVOS</a>) jumped 8.7% to $4.5903 after an independent study showed 97% of Vivos patients achieved their desired treatment outcome.</li>
	<li>Immersion Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMMR#NASDAQ">IMMR</a>) gained 7.2% to $8.81 after the company reported strong preliminary results for its second quarter. The company said it sees Q2 non-GAAP earnings between $0.22 and $0.23 per share, versus analysts&rsquo; estimates of $0.11 per share. Immersion also expects 90% year-over-year growth in its revenue.</li>
</ul>

&nbsp;

<a href="https://www.benzinga.com/investing/best-penny-stocks/">Check out these big penny stock gainers and losers</a>

<h3>Losers</h3>

<ul>
	<li>Bridgeline Digital, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLIN#NASDAQ">BLIN</a>) shares dipped 31.3% to $8.40. Bridgeline Digital reported that a global footwear brand&#39;s Indonesian subsidiary chose the company&rsquo;s Celebros search for online experience.</li>
	<li>BSQUARE Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BSQR#NASDAQ">BSQR</a>) fell 29.1% to $5.00. On July 6, 2021, software solutions provider BSQUARE entered into a Side Letter with B. Riley Securities, Inc to sell shares having an aggregate offering price of up to $50 million under the company&rsquo;s Form S-3 filed on March 18.</li>
	<li>Marin Software Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRIN#NASDAQ">MRIN</a>) fell 25.1% to $18.08 after gaining 19% on Tuesday amid continued extreme volatility and volume in the stock from investors following the company&#39;s Instacart Ads integration announcement..</li>
	<li>Powerbridge Technologies Co Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PBTS#NASDAQ">PBTS</a>) fell 22.6% to $2.33 after surging around 70% on Tuesday.</li>
	<li>IDEAYA Biosciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IDYA#NASDAQ">IDYA</a>) dropped 21.7% to $17.80 after the company offered up to $80 million shares in an underwritten public offering. Underwriters have an option to purchase up to $12 million of shares.</li>
	<li>Red Cat Holdings Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RCAT#NASDAQ">RCAT</a>) shares fell 20.1% to $2.79 after climbing over 37% on Tuesday.</li>
	<li>Cleveland BioLabs, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CBLI#NASDAQ">CBLI</a>) dropped 20% to $4.99. Cleveland BioLabs and Cytocom recently announced a call to discuss the stockholder meeting vote results and proposed merger.</li>
	<li>Professional Diversity Network, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IPDN#NASDAQ">IPDN</a>) fell 19.3% to $1.71 after the company reported a $2.5 million registered direct offering at $1.70 per share.</li>
	<li>Pop Culture Group Co Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CPOP#NASDAQ">CPOP</a>) shares fell 19.2% to $25.46. Pop Culture Group shares dropped over 40% on Tuesday on continued post-IPO volatility.</li>
	<li>Orbsat Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OSAT#NASDAQ">OSAT</a>) shares fell 19% to $6.81. Orbsat shares climbed 54% on Tuesday on abnormally-high volume.</li>
	<li>Wheeler Real Estate Investment Trust, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WHLR#NASDAQ">WHLR</a>) dipped 19% to $3.32 after declining 20% on Tuesday.</li>
	<li>Soligenix, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNGX#NASDAQ">SNGX</a>) fell 17.2% to $1.0850 after jumping 26% on Tuesday.</li>
	<li>Staffing 360 Solutions Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STAF#NASDAQ">STAF</a>) fell 15.4% to $4.0594 after declining around 4% on Tuesday.</li>
	<li>Exela Technologies Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XELA#NASDAQ">XELA</a>) fell 15.3% to $2.2690 after jumping over 42% on Tuesday.</li>
	<li>Amesite Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMST#NASDAQ">AMST</a>) shares fell 14.4% to $2.44 after jumping around 20% on Tuesday.</li>
	<li>Cuentas Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CUEN#NASDAQ">CUEN</a>) dipped 14.3% to $5.15.</li>
	<li>Ocean Power Technologies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OPTT#NYSE">OPTT</a>) dropped 13.8% to $2.4388.</li>
	<li>Portage Biotech Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRTG#NASDAQ">PRTG</a>) fell 13.8% to $18.34. Portage Biotech was recently added to Russell 2000 Index.</li>
	<li>Qumu Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QUMU#NASDAQ">QUMU</a>) declined 13.5% to $2.87 after gaining 15% on Tuesday.</li>
	<li>Manhattan Bridge Capital, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LOAN#NASDAQ">LOAN</a>) fell 13.5% to $6.86 as the company priced its 1.875 million share offering $7.20 per share.</li>
	<li>Tempest Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TPST#NASDAQ">TPST</a>) fell 12.4% to $11.60. Piper Sandler recently initiated coverage on Tempest Therapeutics with an Overweight rating and announced a price target of $23.</li>
	<li>Synaptogenix, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNPX#NASDAQ">SNPX</a>) fell 11.6% to $8.60. Synaptogenix announced a regenerative patent award to treat Alzheimer&#39;s disease.</li>
	<li>Sequential Brands Group Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SQBG#NASDAQ">SQBG</a>) fell 10.8% to $15.15. Sequential Brands gained 8% on Tuesday on above-average volume.</li>
	<li>Axcella Health Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXLA#NASDAQ">AXLA</a>) dropped 9.7% to $3.8901. Axcella Health gained around 9% on Tuesday after HC Wainwright &amp; Co initiated coverage on the stock with a Buy rating and a $14 price target.</li>
	<li>Novavax, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVAX#NASDAQ">NVAX</a>) fell 9.4% to $194.79.</li>
	<li>Nikola Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NKLA#NASDAQ">NKLA</a>) shares declined 8.8% to $14.95. CNH Industrial recently announced a partnership with Nikola.</li>
</ul>

42 Stocks Moving In Wednesday's Mid-Day Session

<h3>Gainers</h3>

<ul>
	<li>Newegg Commerce, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEGG#NASDAQ">NEGG</a>) shares surged 148.4% to close at $67.57 on Wednesday after jumping around 42% on Tuesday.</li>
	<li>Mannatech, Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MTEX#NASDAQ">MTEX</a>) gained 49.7% to settle at $43.71 on Wednesday.</li>
	<li>Data Storage Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DTST#NASDAQ">DTST</a>) shares climbed 32.8% to close at $9.68. Data Storage shares jumped over 24% on Tuesday on above-average volume.</li>
	<li>iPower Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IPW#NASDAQ">IPW</a>) gained 32.2% to settle at $7.72.</li>
	<li>Peabody Energy Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BTU#NYSE">BTU</a>) gained 24.5% to close at $10.01, possibly amid an increase in the price of coal stemming from China unofficially banning Australian coal imports and rising demand in other countries as economies reopen from the pandemic.</li>
	<li>Dar&eacute; Bioscience, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DARE#NASDAQ">DARE</a>) jumped 23.7% to settle at $1.88 on a report suggesting the company entered into an agreement with the Bill &amp; Melinda Gates Foundation and were awarded a new grant of up to $48.95 million to support development of DARE-LARC1.</li>
	<li>Vivos Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VVOS#NASDAQ">VVOS</a>) surged 23.5% to close at $5.20 after an independent study showed 97% of Vivos patients achieved their desired treatment outcome.</li>
	<li>Exela Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XELA#NASDAQ">XELA</a>) jumped 22.8% to settle at $3.29. Exela Technologies said recently-announced at-the-market equity program raised $85 million of proceeds.</li>
	<li>OncoSec Medical Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONCS#NASDAQ">ONCS</a>) shares gained 21.9% to settle at $3.40 after the company said it will evaluate its DNA-plasmid interleukin-12 (IL-12) TAVO (tavokinogene telseplasmid) with Merck &amp; Co&rsquo;s Keytruda (pembrolizumab) in KEYNOTE-C87 Phase 3 trial.</li>
	<li>Opiant Pharmaceuticals Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPNT#NASDAQ">OPNT</a>) shares jumped 21.6% to close at $16.12 after the company disclosed top-line results from its confirmatory pharmacokinetic study for OPNT003, nasal nalmefene, for opioid overdose.</li>
	<li>SMART Global Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGH#NASDAQ">SGH</a>) gained 17.8% to settle at $56.02 after the company reported better-than-expected Q3 results. The company also issued Q4 guidance above analyst estimates.</li>
	<li>G Medical Innovations Holdings Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GMVD#NASDAQ">GMVD</a>) rose 17.6% to close at $4.34. The company, last month priced its IPO at $5 per unit.</li>
	<li>Digital Brands Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DBGI#NASDAQ">DBGI</a>) gained 17.1% to settle at $5.27.</li>
	<li>Virpax Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRPX#NASDAQ">VRPX</a>) climbed 13.9% to close at $5.18 after the company issued a progress update on product candidates.</li>
	<li>Biohaven Pharmaceutical Holding Company Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BHVN#NYSE">BHVN</a>) climbed 13.6% to settle at $112.25. Biohaven reported Q2 NURTEC ODT sales of $93 million.</li>
	<li>X Financial (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XYF#NYSE">XYF</a>) rose 13% to close at $13.13.</li>
	<li>Grom Social Enterprises, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GROM#NASDAQ">GROM</a>) gained 12.8% to settle at $4.05. The company said Curiosity and global production and distribution powerhouse Toon2Tango GmbH &amp; Co. KG will develop Santa.com into an original animated musical holiday special.</li>
	<li>KBS Fashion Group Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KBSF#NASDAQ">KBSF</a>) gained 12.4% to close at $4.44.</li>
	<li>IVERIC bio, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISEE#NASDAQ">ISEE</a>) surged 11.9% to close at $9.61. IVERIC recently announced it received written agreement from the FDA under a Special Protocol Assessment for the overall design of the company&#39;s GATHER2 Phase 3 trial of Zimura.</li>
	<li>Bon Natural Life Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BON#NASDAQ">BON</a>) rose 11% to settle at $11.30. Bon Natural Life recently received the certificate of a land use right for the future site of its third production facility in the city of Yumen.</li>
	<li>Nova LifeStyle, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVFY#NASDAQ">NVFY</a>) gained 10.8% to close at $3.79.</li>
	<li>JinkoSolar Holding Co., Ltd(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JKS#NYSE">JKS</a>) shares climbed 10.7% to settle at $60.14 after gaining around 8% on Tuesday.</li>
	<li>INmune Bio, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INMB#NASDAQ">INMB</a>) jumped 10.6% to close at $19.75.</li>
	<li>CareMax, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMAX#NASDAQ">CMAX</a>) gained 9.7% to settle at $13.80. CareMax recently entered into an agreement to acquire DNF Medical Centers.</li>
	<li>Femasys Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FEMY#NASDAQ">FEMY</a>) surged 9.3% to settle at $7.75. The company, lats month, priced its IPO at $13 a share.</li>
	<li>Performant Financial Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PFMT#NASDAQ">PFMT</a>) gained 9.1% to close at $3.71. Craig-Hallum initiated coverage on Performant Financial with a Buy rating and announced a price target of $10.</li>
	<li>iSpecimen Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISPC#NASDAQ">ISPC</a>) gained 8.1% to close at $6.70. The company, last month, priced its IPO at $8 per share.</li>
</ul>

&nbsp;

 
<a href="https://www.benzinga.com/investing/best-penny-stocks/">Check out these big penny stock gainers and losers</a>

<h3>Losers</h3>

<ul>
	<li>Bridgeline Digital, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLIN#NASDAQ">BLIN</a>) shares tumbled 30.1% to close at $8.55 on Wednesday. Bridgeline Digital reported that a global footwear brand&#39;s Indonesian subsidiary chose the company&rsquo;s Celebros search for online experience.</li>
	<li>BSQUARE Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BSQR#NASDAQ">BSQR</a>) dropped 28.4% to close at $5.05. On July 6, 2021, software solutions provider BSQUARE entered into a Side Letter with B. Riley Securities, Inc to sell shares having an aggregate offering price of up to $50 million under the company&rsquo;s Form S-3 filed on March 18.</li>
	<li>Professional Diversity Network, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IPDN#NASDAQ">IPDN</a>) dipped 20.8% to close at $1.68 after the company reported a $2.5 million registered direct offering at $1.70 per share.</li>
	<li>Eco Wave Power Global AB (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WAVE#NASDAQ">WAVE</a>) dropped 20.4% to settle at $14.85. A 13G filing from Alpha Capital recently showed an 8.7% stake in the company.</li>
	<li>Marin Software Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRIN#NASDAQ">MRIN</a>) fell 20.3% to close at $19.24 after gaining gained 19% on Tuesday amid continued extreme volatility and volume in the stock from investors following the company&#39;s Instacart Ads integration announcement..</li>
	<li>IDEAYA Biosciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IDYA#NASDAQ">IDYA</a>) declined 20.3% to close at $18.11 after the company offered up to $80 million shares in an underwritten public offering. Underwriters have an option to purchase up to $12 million of shares.</li>
	<li>Staffing 360 Solutions Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STAF#NASDAQ">STAF</a>) dipped 20.2% to close at $3.83 after declining around 4% on Tuesday.</li>
	<li>Meta Materials Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MMAT#NASDAQ">MMAT</a>) dropped 19.3% to settle at $5.80. Meta Materials, formerly known as Torchlight Energy Resources Inc, recently performed a reverse split and merged with the company Meta Materials Inc. to become a combined company under the ticker MMAT.</li>
	<li>Cleveland BioLabs, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CBLI#NASDAQ">CBLI</a>) fell 18.9% to close at $5.06. Cleveland BioLabs and Cytocom recently announced a call to discuss the stockholder meeting vote results and proposed merger.</li>
	<li>Mercurity Fintech Holding Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MFH#NASDAQ">MFH</a>) dropped 18.5% to close at $4.20.</li>
	<li>Powerbridge Technologies Co Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PBTS#NASDAQ">PBTS</a>) declined 18.4% to settle at $2.49 after surging around 70% on Tuesday.</li>
	<li>iClick Interactive Asia Group Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICLK#NASDAQ">ICLK</a>) fell 17.6% to close at $8.92.</li>
	<li>SemiLEDs Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LEDS#NASDAQ">LEDS</a>) dipped 17.6% to settle at $13.50. SemiLEDs said, on July 6, it entered into a sales agreement with Roth Capital Partners.</li>
	<li>Tempest Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TPST#NASDAQ">TPST</a>) fell 17.5% to close at $10.93. Piper Sandler recently initiated coverage on Tempest Therapeutics with an Overweight rating and announced a price target of $23.</li>
	<li>Red Cat Holdings Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RCAT#NASDAQ">RCAT</a>) shares dropped 16.9% to close at $2.90 after climbing over 37% on Tuesday.</li>
	<li>Pop Culture Group Co Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CPOP#NASDAQ">CPOP</a>) shares declined 16.7% to close at $26.26. Pop Culture Group shares dropped over 40% on Tuesday on continued post-IPO volatility.</li>
	<li>Wheeler Real Estate Investment Trust, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WHLR#NASDAQ">WHLR</a>) dropped 16.6% to close at $3.42 after declining 20% on Tuesday.</li>
	<li>Manhattan Bridge Capital, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LOAN#NASDAQ">LOAN</a>) dropped 16.1% to close at $6.65 as the company priced its 1.875 million share offering $7.20 per share.</li>
	<li>Soligenix, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNGX#NASDAQ">SNGX</a>) dropped 16% to settle at $1.10 after jumping 26% on Tuesday.</li>
	<li>Auddia Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AUUD#NASDAQ">AUUD</a>) fell 15.4% to close at $5.81. Auddia recently named RadioAlabama as the third radio station group on the Auddia platform.</li>
	<li>Amesite Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMST#NASDAQ">AMST</a>) shares dropped 14.4% to close at $2.44 after jumping around 20% on Tuesday.</li>
	<li>Ocean Power Technologies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OPTT#NYSE">OPTT</a>) fell 14.1% to close at $2.43.</li>
	<li>ACM Research, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACMR#NASDAQ">ACMR</a>) dropped 13.9% to settle at $84.23.</li>
	<li>Novavax, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVAX#NASDAQ">NVAX</a>) dipped 13.7% to close at $185.78.</li>
	<li>Support.com, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPRT#NASDAQ">SPRT</a>) dropped 13.2% to settle at $4.27.</li>
	<li>Synaptogenix, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNPX#NASDAQ">SNPX</a>) fell 13.2% to close at $8.45. Synaptogenix announced a regenerative patent award to treat Alzheimer&#39;s disease.</li>
	<li>Zhihu Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZH#NYSE">ZH</a>) tumbled 12.7% to settle at $9.25.</li>
	<li>Sequential Brands Group Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SQBG#NASDAQ">SQBG</a>) fell 12.1% to close at $14.92. Sequential Brands gained 8% on Tuesday on above-average volume.</li>
	<li>Cuentas Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CUEN#NASDAQ">CUEN</a>) dipped 11.7% to close at $5.31.</li>
	<li>Orbsat Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OSAT#NASDAQ">OSAT</a>) shares declined 10.8% to close at $7.49. Orbsat shares climbed 54% on Tuesday on abnormally-high volume.</li>
	<li>Qumu Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QUMU#NASDAQ">QUMU</a>) slipped 9.9% to close at $2.99 after gaining 15% on Tuesday.</li>
	<li>Portage Biotech Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRTG#NASDAQ">PRTG</a>) dropped 8.7% to close at $19.43. Portage Biotech was recently added to Russell 2000 Index.</li>
	<li>Axcella Health Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXLA#NASDAQ">AXLA</a>) dropped 7.2% to close at $4.00. Axcella Health gained around 9% on Tuesday after HC Wainwright &amp; Co initiated coverage on the stock with a Buy rating and a $14 price target.</li>
	<li>Nikola Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NKLA#NASDAQ">NKLA</a>) shares slipped 6.8% to close at $15.28. CNH Industrial recently announced a partnership with Nikola.</li>
</ul>

61 Biggest Movers From Yesterday

<h3>Gainers</h3>

<ul>
	<li>Sentage Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNTG#NASDAQ">SNTG</a>) shares surged 597.8% to settle at $34.89 on Friday as the company priced its IPO at $5 per share.</li>
	<li>SGOCO Group, Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGOC#NASDAQ">SGOC</a>) shares jumped 279.5% to close at $9.79 on Friday as markets rebounded following a selloff in the previous session over concerns the economic recovery is slowing as the COVID-19 Delta variant spreads.</li>
	<li>Stamps.com Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STMP#NASDAQ">STMP</a>) surged 64% to close at $324.23 on Friday. Software investment firm Thoma Bravo inked an agreement to acquire e-commerce shipping solutions provider Stamps.com in an all-cash transaction valued at $6.6 billion.</li>
	<li>Tempest Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TPST#NASDAQ">TPST</a>) gained 49.4% to settle at $15.67. Piper Sandler, last week, initiated coverage on Tempest Therapeutics with an Overweight rating and announced a price target of $23.</li>
	<li>Toughbuilt Industries Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TBLT#NASDAQ">TBLT</a>) shares surged 45.8% to close at $1.05 after the company reported 1H sales through Amazon of $5.48 million, up 118% year over year.</li>
	<li>TransCode Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RNAZ#NASDAQ">RNAZ</a>) rose 32.3% to close at $5.29 after the company priced its IPO at $4 per share.</li>
	<li>Lucira Health, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LHDX#NASDAQ">LHDX</a>) gained 29.2% to settle at $8.50.</li>
	<li>Mer Telemanagement Solutions Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MTSL#NASDAQ">MTSL</a>) surged 26.4% to close at $4.74.</li>
	<li>Galectin Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GALT#NASDAQ">GALT</a>) shares gained 25% to close at $3.45. after the company announced top-line clinical data from the extension cohort of Phase 1b trial of Belapectin in combination with Merck &amp; Co&rsquo;s Keytruda (pembrolizumab) in patients with metastatic melanoma and head &amp; neck cancer.</li>
	<li>AgriFORCE Growing Systems Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGRI#NASDAQ">AGRI</a>) surged 21.5% to settle at $5.60 as the company priced its IPO at $5 per unit.</li>
	<li>Carver Bancorp, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CARV#NASDAQ">CARV</a>) shares gained 21.1% to settle at $26.50 as traders play the stock as a high-short interest name.</li>
	<li>MediaCo Holding Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDIA#NASDAQ">MDIA</a>) rose 20.1% to close at $4.13.</li>
	<li>BriaCell Therapeutics Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCTX#NASDAQ">BCTX</a>) gained 18.3% to settle at $5.63.</li>
	<li>NRx Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NRXP#NASDAQ">NRXP</a>) jumped 16.9% to close at $11.51.</li>
	<li>LMP Automotive Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LMPX#NASDAQ">LMPX</a>) shares gained 16.2% to close at $15.98 after the company reported that the board authorized debt refinancing.</li>
	<li>Kanzhun Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BZ#NASDAQ">BZ</a>) gained 15.9% to close at $36.17.</li>
	<li>Infobird Co., Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IFBD#NASDAQ">IFBD</a>) rose 15.2% to settle at $4.17.</li>
	<li>Portage Biotech Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRTG#NASDAQ">PRTG</a>) gained 15% to close at $22.08. Portage Biotech was recently added to Russell 2000 Index.</li>
	<li>Pitney Bowes Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PBI#NYSE">PBI</a>) surged 14.9% to close at $9.43.</li>
	<li>Aehr Test Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AEHR#NASDAQ">AEHR</a>) shares rose 14.8% to close at $2.72 after the company said it received a $2.9 million follow-on order for a FOX-XP&trade; Wafer Level Test and Burn-in system and multiple WaferPak&trade; Contactors for production test.</li>
	<li>Hallmark Financial Services, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HALL#NASDAQ">HALL</a>) surged 14.8% to close at $4.96.</li>
	<li>PHX Minerals Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PHX#NYSE">PHX</a>) gained 14.6% to close at $3.76.</li>
	<li>Global Internet of People, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SDH#NASDAQ">SDH</a>) gained 14.6% to close at $3.53.</li>
	<li>Performant Financial Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PFMT#NASDAQ">PFMT</a>) surged 14.4% to settle at $3.97. Craig-Hallum, last week, initiated coverage on Performant Financial with a Buy rating and announced a price target of $10.</li>
	<li>TDH Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PETZ#NASDAQ">PETZ</a>) rose 14.3% to close at $2.56.</li>
	<li>Sprinklr, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CXM#NYSE">CXM</a>) surged 14.3% to settle at $22.37.</li>
	<li>Presidio Property Trust, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SQFT#NASDAQ">SQFT</a>) gained 14% to close at $5.13.</li>
	<li>INmune Bio, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INMB#NASDAQ">INMB</a>) gained 13.5% to close at $22.97.</li>
	<li>The OLB Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OLB#NASDAQ">OLB</a>) rose 13% to settle at $6.24.</li>
	<li>Chico&#39;s FAS, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHS#NYSE">CHS</a>) gained 13% to close at $6.97.</li>
	<li>Niu Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NIU#NASDAQ">NIU</a>) surged 11.8% to settle at $33.86.</li>
	<li>89bio, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ETNB#NASDAQ">ETNB</a>) climbed 11.7% to close at $17.89.</li>
	<li>AZZ Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AZZ#NYSE">AZZ</a>) gained 11.7% to close at $57.57 as the company reported better-than-expected results for its first quarter and raised profit forecast for FY22.</li>
	<li>indie Semiconductor, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INDI#NASDAQ">INDI</a>) jumped 9.6% to close at $9.06. indie Semiconductor is expected to discuss its Q2 2021 results and business outlook on August 10, 2021.</li>
	<li>Recon Technology, Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RCON#NASDAQ">RCON</a>) gained 9.6% to close at $3.76. Recon Technology&rsquo;s Subsidiary FGS recently signed a cooperation agreement with Gao Deng.</li>
	<li>Sequential Brands Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SQBG#NASDAQ">SQBG</a>) gained 9.1% to settle at $13.48 after dropping 17% on Thursday.</li>
	<li>TAL Education Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TAL#NYSE">TAL</a>) jumped 8.8% to close at $21.22.</li>
	<li>LightPath Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LPTH#NASDAQ">LPTH</a>) shares jumped 8.2% to close at $2.51 after the company announced it was awarded the renewal of a multiyear supply agreement valued above $2.4 million.</li>
	<li>ReShape Lifesciences Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RSLS#NASDAQ">RSLS</a>) fell 7.7% to close at $4.69 after jumping around 24% on Thursday. The company recently highlightsed completion of lap-band manufacturing transition to Massachusetts-based manufacturer.</li>
	<li>Prothena Corporation plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRTA#NASDAQ">PRTA</a>) rose 7.3% to close at $59.24.</li>
	<li>BioNTech SE - ADR (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNTX#NASDAQ">BNTX</a>) rose 4.6% to close at $217.40. Pfizer and BioNTech started designing version of COVID-19 vaccine specifically to combat Delta variant.</li>
</ul>

 
<a href="https://www.benzinga.com/investing/best-penny-stocks/">Check out these big penny stock gainers and losers</a>

<h3>Losers</h3>

<ul>
	<li>Moving iMage Technologies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MITQ#NYSE">MITQ</a>) fell 33.5% to settle at $15.95 on Friday after jumping 700% on Thursday. Moving iMage Technologies priced its initial public offering of 4.2 million common shares at $3 per share.</li>
	<li>Nova LifeStyle, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVFY#NASDAQ">NVFY</a>) shares fell 27.4% to close at $4.72 on Friday after jumping over 71% on Thursday.</li>
	<li>Sigilon Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGTX#NASDAQ">SGTX</a>) dipped 25.3% to close at $6.90 The FDA has instituted a clinical hold on Sigilon Therapeutics Phase 1/2 study of SIG-001 in patients with severe or moderately severe hemophilia A.</li>
	<li>Universal Security Instruments, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UUU#NYSE">UUU</a>) fell 23.3% to close at $6.90 after reporting a loss for its fourth quarter.</li>
	<li>Meta Materials Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MMAT#NASDAQ">MMAT</a>) fell 17.4% to close at $4.75.</li>
	<li>Bon Natural Life Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BON#NASDAQ">BON</a>) fell 17.1% to close at $9.42.</li>
	<li>LM Funding America Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LMFA#NASDAQ">LMFA</a>) dropped 17% to close at $4.69 after surging 42% on Thursday.</li>
	<li>Alterity Therapeutics Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATHE#NASDAQ">ATHE</a>) fell 16.8% to close at $1.68 after climbing 28% on Thursday. The company&#39;s Australian-listed stock recently filed for a proposed offering of shares.</li>
	<li>Digital Brands Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DBGI#NASDAQ">DBGI</a>) dropped 15.1% to settle at $5.07. Digital Brands Group recently estimated a 100% jump in its second quarter FY21 revenue on a sequential basis. It reported $0.41 million sales for the first quarter of FY21.</li>
	<li>Takung Art Co., Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TKAT#NASDAQ">TKAT</a>) dropped 14.1% to close at $10.19.</li>
	<li>UTime Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UTME#NASDAQ">UTME</a>) fell 12.9% to close at $11.22 in pre-market trading. UTime shares jumped 43% on Thursday on abnormally high volume.</li>
	<li>Bridgeline Digital, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLIN#NASDAQ">BLIN</a>) dipped 11.9% to close at $6.76.</li>
	<li>Siebert Financial Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SIEB#NASDAQ">SIEB</a>) dropped 11.2% to settle at $4.62 after gaining 14% on Thursday.</li>
	<li>Aerpio Pharmaceuticals Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARPO#NASDAQ">ARPO</a>) shares dipped 10.4% to close at $2.50. Aerpio Pharmaceuticals shares gained 63% on Thursday after HC Wainwright &amp; Co. upgraded the company&#39;s stock from Neutral to Buy and announced a $22price target.</li>
	<li>Cassava Sciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAVA#NASDAQ">SAVA</a>) dropped 10.1% to settle at $95.34 after STAT news reported &#39;FDA calls for federal investigation into [Biogen&#39;s] controversial Alzheimer&#39;s drug approval.&#39;</li>
	<li>OncoSec Medical Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONCS#NASDAQ">ONCS</a>) fell 9.7% to close at $2.88. OncoSec Medical recent said it entered into a Clinical Trial Collaboration and Supply Agreement with Merck to evaluate the combination of OncoSec&#39;s TAVO with Merck&#39;s KEYTRUDA in a Phase 3 study.</li>
	<li>Grom Social Enterprises, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GROM#NASDAQ">GROM</a>) dropped 9.6% to settle at $3.56.</li>
	<li>Wheeler Real Estate Investment Trust, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WHLR#NASDAQ">WHLR</a>) fell 8.9% to settle at $3.26.</li>
	<li>Staffing 360 Solutions, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STAF#NASDAQ">STAF</a>) dropped 8.6% to close at $3.49.</li>
	<li>Cohen &amp; Company Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COHN#NYSE">COHN</a>) slipped 8.2% to settle at $24.83.</li>
	<li>Alussa Energy Acquisition Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FREY#NYSE">FREY</a>) fell 6.9% to close at $8.80.</li>
	<li>Xtant Medical Holdings Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XTNT#NASDAQ">XTNT</a>) shares fell 6% to close at $1.74. Shares of Xtant Medical gained 23% on Thursday on below-average volume.</li>
	<li>Vivos Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VVOS#NASDAQ">VVOS</a>) fell 5.5% to close at $4.63. An independent study recently showed 97% of Vivos patients achieved their desired treatment outcome.</li>
</ul>

Recent Quotes

Related Companies

Portage Biotech Frequently Asked Questions

How do I buy Portage Biotech (PRTG) stock?

Who are Portage Biotech's (PRTG) competitors?

What is the target price for Portage Biotech (PRTG) stock?

Current Stock Price for Portage Biotech (PRTG)?

Does Portage Biotech (PRTG) pay a dividend?

When is Portage Biotech (NASDAQ:PRTG) reporting earnings?

Is Portage Biotech (PRTG) going to split?

What sector and industry does Portage Biotech (PRTG) operate in?